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ABSTRACT  
   
Ebola hemorrhagic fever (EHF) is a severe and often fatal disease 
in human and nonhuman primates, caused by the Ebola virus. 
Approximately 30 years after the first epidemic, there is no vaccine or 
therapeutic medication approved to counter the Ebola virus. 
In this dissertation, a geminiviral replicon system was used to 
produce Ebola immune complex (EIC) in plant leaves and tested it as an 
Ebola vaccine. The EIC was produced in Nicotiana benthamiana leaves 
by fusing Ebola virus glycoprotein (GP1) to the C-terminus of heavy chain 
of 6D8 monoclonal antibody (mAb), which is specific to the 6D8 epitope of 
GP1, and co-expressing the fusion with the light chain of 6D8 mAb. EIC 
was purified by ammonium sulfate precipitation and protein A or protein G 
affinity chromatography. EIC was shown to be immunogenic in mice, but 
the level of antibody against Ebola virus was not sufficient to protect the 
mice from lethal the Ebola challenge.  
Hence, different adjuvants were tested in order to improve the 
immunogenicity of the EIC. Among several adjuvants that we used, 
Poly(I:C), which is a synthetic analog of double-stranded ribonucleic acid 
that can interact with a Toll-like receptor 3, strongly increased the efficacy 
of our Ebola vaccine. The mice immunized with EIC co-administered with 
Poly(I:C) produced high levels of neutralizing anti-Ebola IgG, and 80% of 
the mice were protected from the lethal Ebola virus challenge. Moreover, 
the EIC induced a predominant T-helper type 1 (Th1) response, whereas 
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Poly(I:C) co-delivered with the EIC stimulated a mixed Th1/Th2 response. 
This result suggests that the protection against lethal Ebola challenge 
requires both Th1 and Th2 responses.  
In conclusion, this study demonstrated that the plant-produced EIC 
co-delivered with Poly(I:C) induced strong and protective immune 
responses to the Ebola virus in mice. These results support plant-
produced EIC as a good vaccine candidate against the Ebola virus. It 
should be pursued further in primate studies, and eventually in clinical 
trials.  
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Chapter 1 
INTRODUCTION 
Ebola hemorrhagic fever (EHF) is a severe and often deadly 
disease that occurs in human and nonhuman primates, such as 
chimpanzees, monkeys, and gorillas (59). In humans, Ebola virus causes 
a lethal hemorrhagic disease with very high mortality rates, up to 90%, 
and with clinical symptoms arising quickly after an incubation period of 2 
to 21 days (43). The typical presentation is characterized by flu-like 
symptoms including high fever, chills, malaise, and myalgia. Taken 
together, the ensuing symptoms indicate multisystem involvement, 
including systemic, gastrointestinal, respiratory, vascular, and neurologic 
manifestations. Abnormalities in blood coagulation appear as petechiae, 
ecchymoses, mucosal hemorrhages, and uncontrolled bleeding in 
venipuncture sites. Severe Ebola infections usually progress to shock, 
convulsions, and diffuse coagulopathy. Within 6 to 9 days after the onset 
of clinical symptoms, death may occur or recovery begins. The dramatic 
clinical symptoms and a high fatality rate associated with Ebola virus 
infection make it an extremely dangerous pathogen. Moreover, all Ebola 
virus strains have demonstrated the ability to be spread through aerosols 
under research conditions. Therefore, Ebola virus poses severe threat 
human populations and is a potential candidate for a biowarfare agent that 
can be used by terrorists. Approximately 30 years after the first epidemic, 
there is still no approved vaccine or therapeutic for the Ebola virus. 
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Epidemiology 
The name Ebola originates from the Ebola River in the Democratic 
Republic of Congo, where the first documented outbreak occurred in 1976 
(19). There have been four strains of the Ebola virus identified—the 
Sudan, Zaire, Reston, and Ivory Coast strains—differing by approximately 
30–40% in their nucleotide sequences (83). In the first documented 
outbreak of Ebola in June 1976, the strain Sudan infected 284 people with 
a mortality rate of 53%. Several months later, a second Ebola epidemic 
occurred in the Democratic Republic of Congo (previously known as 
Zaire); there, the Ebola strain Zaire infected 318 people and had the 
highest mortality rate of 88% (98). In these two outbreaks, there was 
significant secondary transmission through reuse of unsterilized needles 
and syringes and in hospital contacts. The primary transmission in these 
two outbreaks, however, is not clearly known; it might have resulted from 
contact with infected animals. The third Ebola strain, Reston, was found in 
1989, when infected monkeys were imported to Reston, Virginia, from the 
Philippines. Hundreds of monkeys were infected with this strain and 
experienced a high mortality rate. Fortunately, few people were infected in 
this incident, and no human developed EHF. The fourth strain, known as 
the Ivory Coast strain, was identified in Côte d'Ivoire in1994 (6). This strain 
was associated with chimpanzees; the only identified human infection 
proved to be non-fatal (49). Among these four strains, Zaire has the 
highest morbidity/mortality rate followed by the Sudan and Ivory Coast 
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strains, respectively; the Reston strain caused disease only in nonhuman 
primates. Since the discovery of the virus, the World Health Organization 
(WHO) has reported approximately 1,850 cases with over 1,200 deaths 
from Ebola virus infection. Epidemiological history suggests that the 
countries in the mid-western part of Africa are the epicenter for Ebola virus 
infections. Although a natural reservoir of the Ebola virus has not yet been 
identified, based on the evidence, the reservoir is suspected to reside in 
the rain forest in western Africa.  
Clinical Syndrome 
The Ebola virus is transmitted in nature through direct contact with 
infected bodily fluids (e.g., blood, semen, and vaginal fluid) of infected 
persons or primates (17). When the virus infects a human, it enters the 
body and starts replicating in mononuclear phagocytic cells such as 
macrophages and monocytes (26, 29, 63, 76). After infection in these 
primary target cells in the blood, continued virus production in these cells 
causes high viremia, which allows the virus to be disseminated throughout 
the bloodstream and to infect secondary target cells, such as endothelial 
cells in the liver, spleen, pancreas, lungs, and kidneys. Viral infection of 
various organs leads to the disease symptoms associated with multi-organ 
failure, such as prostration, lethargy, anorexia, nausea, vomiting, 
abdominal pain, diarrhea, chest pain, shortness of breath, cough, 
conjunctival injection, postural hypotension, edema, headache, confusion, 
seizure, and coma. 
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Ebola Virus 
Ebola virus is a Filovirus belonging to the Filoviridae family. It is usually 80 
nm in diameter and variable in length (28). The 19-kilobase genome of 
Ebola consists of nonsegmented negative sense RNA and encodes a total 
of seven proteins:  3’ nucleoprotein (NP), virion protein (VP) 35, virion 
protein 40 (VP40), glycoprotein (GP), virion protein 30 (VP30), virion 
protein 24 (VP24), and polymerase (L) 5’. The nucleoprotein, virion protein 
35, virion protein 30, and polymerase are associated with the genome of 
Ebola virus as a ribonucleoprotein complex inside the virus, whereas 
virion protein 40, virion protein 24, and glycoprotein are associated with 
the membrane (18). These proteins are translated from polyadenylated 
mRNA, which is transcribed from the viral RNA in the host cell. The 
ribonucleoprotein complex is surrounded by an envelope that originates 
from the host cell membrane. VP40 and VP24 form the virion envelope 
(18, 57, 62). The fourth gene of the Ebola genome encodes a soluble 
nonstructural secreted glycoprotein (sGP) and a structural transmembrane 
glycoprotein (GP). GP is expressed by transcriptional editing, resulting in 
the addition of an extra adenosine within a run of seven adenosines in the 
coding sequence (86). GP and sGP share roughly 300 amino-terminal 
amino acids. GP has additional 380 carboxy-terminal amino acids, 
whereas sGP has 70 additional carboxy-terminal amino acids (79). 
Previous cell culture studies demonstrated that the majority of GP mRNA 
is not edited and encodes nonstructural sGP, which accumulates in the 
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infected cell media (64, 87). Thus, the primary gene product of the Ebola 
GP gene is not the transmembrane GP, but rather the sGP. The function 
of sGP is not fully understood, but it has been suggested that sGP might 
play a role in immune evasion by acting as a decoy molecule that binds to 
Ebola-specific antibodies and therefore limits the opportunity for 
antibodies to neutralize the virus (39, 105). Takada and Kawaoka (1998) 
showed that sGP can bind to neutrophils via CD16b, which is a neutrophil-
specific form of Fc gamma receptor III, and inhibit early neutrophil 
activation (80). Another possible function of sGP is to bind to neutrophils 
and consequently inhibit their activation. The only viral protein that is 
detected on the surface of the virus and the infected cell is GP, which 
forms spikes on the viral envelope (23, 89). The GP spike on the viral 
envelope is responsible for attaching to the receptors (e.g., dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-integrin (DC-
SIGN), liver/lymph node-specific intercellular adhesion molecule-3-
grabbing integrin (L-SIGN), or folate receptor) and entering into the cell by 
membrane fusion (81, 101). Transmembrane GP is cleaved 
posttranslationally by furin into N-terminal GP1 and C-terminal GP2 (65, 
88). GP1 is linked with GP2 by disulfide bonds and is present as a trimer 
in the spike of the virus (4, 50). GP expression causes cell rounding and 
detachment in cultured human endothelial and epithelial cells, which are 
the target cells for Ebola virus infection (71, 106). This effect requires the 
mucin-like domain in GP and correlates with the down regulation of 
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specific molecules on the cell surface such as beta1 integrin and major 
histocompatibility complex class I (24, 82). This evidence supports the 
idea that Ebola GP can induce protein down modulation and cytopathic 
effects. 
Pathogenesis 
The molecular mechanism of Ebola pathogenesis is difficult to 
understand due to the rapid onset of disease symptoms and death in 
nature and also in laboratory animal models. Research on this virus 
requires Biosafety Level 4 (BSL-4) facilities—the most stringent degree of 
laboratory protection. BSL-4 labs are designated for work with dangerous 
and exotic agents that pose a high individual risk of aerosol-transmitted 
laboratory infections, cause severe or fatal disease in humans, and for 
which there are no vaccines or treatments available. The low number of 
laboratories designated BSL-4 in the world limits Ebola virus research. 
The first step of the infection is binding of GP to receptors on the 
cell surface. The receptor for Ebola virus has not been definitively 
identified, but previous studies showed that possible receptors are DC-
SIGN, L-SIGN, and folate receptor. DC-SIGN was shown to bind with the 
Ebola glycoproteins and enhance Ebola infection. It is expressed in many 
cell types such as dendritic cells, macrophages, and endothelial cells in 
the liver and lymph nodes, which are the target cells for Ebola virus 
infection (70). L-SIGN is not expressed by dendritic cells, but is expressed 
on the surface of endothelial cells in the liver, lymph node sinuses, and 
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placenta villi (5). Wool-Lewis and Bates (101) used the Jurkat cell line, 
which is an immortalized line of T lymphocyte cells, nonpermissive for 
Ebola virus infection and considered to be receptor deficient, to identify 
the Ebola virus receptor. They found that when the Jurkat cells expressed 
L-SIGN, they could be infected with Ebola virus (1). This result indicated 
that L-SIGN can mediate an Ebola virus infection. Another possible 
receptor for GP is the folate receptor. Jurkat cells expressing the folate 
receptor also showed infection with Ebola virus (11). Macrophages and 
fibroblasts are examples of cells that express folate receptors, and they 
are target cells for Ebola virus infection. This result supports the possibility 
that the folate receptor is a receptor for Ebola infection. 
 Ebola virus infection in endothelial cells via GP spike/cell receptor 
interaction shows the destruction of the cells associated with disseminated 
intravascular coagulation (67). Therefore, the specific binding of GP may 
play a role in the pathology of Ebola virus infection. All evidence has 
shown that the Ebola GP is the only protein on the viral cell surface. 
Moreover, these results suggest that the Ebola GP is the protein that 
causes viral infection by binding to host cell receptors and also causes the 
cytopathic effect. Thus, the Ebola GP is one of the target proteins for 
Ebola vaccine development.  
The primary difficulty for patients in recovering from Ebola virus 
infections results from failure of their immune systems to react to this fast-
developing disease. The patients who die from Ebola hemorrhagic fever 
  8 
are unable to develop an adequate immune response in the face of 
extreme viremia and multi-organ infection. Previous studies have shown 
that survivors of Ebola infection must develop early and increasing levels 
of IgG against Ebola virus, followed by viral antigen clearance and 
cytotoxic T cell activation. In fatal cases, Ebola-specific IgG and T cell-
related mRNA cannot be detected (3). These data imply that both 
humoral- and cell-mediated immune responses are important for recovery 
from Ebola virus infection. Thus, the key for Ebola vaccine development is 
to activate both antibody (Ab) response and cytotoxic T cells against the 
Ebola virus.  
 There are different animal models developed for study of the Ebola 
virus infection including mouse, guinea pig, and nonhuman primates, but 
the “gold standard” animal models for pathogenesis, treatment, and 
vaccine studies are rhesus and cynomolgus macaques. Only these 
animals are lethally infected with non-adapted human isolates, and the 
resulting pathology is close to the pathology described in humans.  
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Therapeutic Drugs for Ebola Infection 
Currently, there is no approved treatment or cure for Ebola virus 
infection. However, there are several candidates being researched as 
applications for Ebola therapeutics, including neutralizing antibodies, 
Vesicular stomatitis virus-vectored vaccine (post-exposure), and the use 
of an anticoagulant protein.   
Neutralizing antibodies have been studied in the treatment of 
Ebola-infected animals. The anti-Ebola virus IgG from equine has been 
shown to protect cynomolgus monkeys and baboons from infection when 
it is injected before or after infection at a high dose of IgG (40, 45). Wilson 
et al. (100) found that the passive transfer of mAb against Ebola GP can 
protect mice from Ebola infection. Moreover, passive transfer of serum 
from mice that have survived Ebola virus infection can protect naïve mice 
against lethal challenge (31). Although passive transfer can protect mice 
from Ebola lethal infection, it is only effective with the presence of a high 
Ab titer in the serum (41). At similar comparable doses, it has been less 
successful in protecting non-human primates. Therefore, the passive 
transfer strategy may not be a promising therapeutic for human treatment.   
 There are also studies to support Vesicular stomatitis virus (VSV)-
based Ebola vaccine as a means of post-exposure prevention. When 
treated 24 hours after an Ebola intraperitoneal challenge with VSV-
expressing Ebola GP, mice showed complete protection from Ebola virus 
challenge. However, less encouraging results were obtained when this 
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experiment was repeated in guinea pigs, the survival rate being 
approximately 50% (22). The most persuasive results show that VSV-
expressed Ebola GP post-exposure treatment protected cynomolgus 
macaques against aerosol exposure of Ebola virus (25). Although VSV-
based Ebola vaccine showed promising protection in the macaques, the 
results are not consistent in different animals.  
Another possibility for an Ebola therapeutic is the use of an 
anticoagulant protein. Previous data showed that Ebola-infected 
macrophage express a tissue factor, which is a clotting protein on the cell 
surface that attracts other blood clotting proteins. The accumulation of 
these blood clotting proteins causes the body to become vulnerable to 
bleeding, the symptom that leads to fatality (20). Recombinant nematode 
anticoagulant protein c2 (rNAPc2), which is a potent inhibitor of tissue 
factor-initiated blood coagulation, has been studied as an Ebola 
therapeutic. The treatment of monkeys with rNAPc2 immediately or within 
24 hours after infection and continuing for eight days saved three out of 
nine monkeys and delayed the death of the other six monkeys (27). 
Although this protein can reduce the mortality rate only by about 30%, the 
reduction is significant because the infection of rhesus monkeys is almost 
always lethal.  
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Ebola Vaccine Development 
Not only is there no approved Ebola virus therapeutic, but there is 
no licensed Ebola vaccine for human use at this time. Much research is 
focused on developing an Ebola vaccine, but the results have not been 
promising. There are two major types of Ebola vaccine being researched, 
DNA vaccine and viral-based vector. The viral-based vector includes 
different strategies such as the use of a virus-like particle or a viral 
replicon that can replicate in cells but is not infectious.  
 The first Ebola vaccine tested was a DNA vaccine, which used a 
eukaryotic expression vector with the cytomegalovirus (CMV) immediate 
early region enhancer to stimulate transcription for a high level of gene 
expression in muscle (51). DNA vaccine expressing Ebola GP or NP 
genes showed protection in mice (85, 102). Guinea pigs that were 
immunized with plasmids encoding Ebola NP, GP, or sGP were also 
protected against Ebola infection. Both humoral Ab and T cell-mediated 
responses are detected with this immunization. In a phase I clinical trial, 
the DNA vaccine also showed safety and immunogenicity (52). To 
improve the DNA vaccine efficacy, an Adenovirus vector was 
subsequently used for study in a prime-boost experiment. When priming 
with the DNA vaccine expressing Ebola GP was followed by boosting with 
the Adenovirus vector-expressed Ebola GP, cynomolgus macaques were 
completely protected against a challenge with a lethal dose of Ebola Zaire 
(77). Another study employing prime-boost strategy for the Marburg virus, 
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which is another member of Filovirus family, showed that a priming dose 
of a DNA vaccine expressing the Marburg GP, followed by boosting with a 
recombinant baculovirus-derived GP protein, provided protective immunity 
to guinea pigs (36). Nevertheless, a similar prime-boost experiment did 
not protect against Ebola virus infection in guinea pigs (54). Although it 
may be safe to use the DNA vaccine in humans, the efficacy of a DNA 
vaccine needs more study.  
 Another strategy for vaccine development is to use a viral-based 
vector. The first type is a virus-like particle (VLP), which contains proteins 
that form envelope and surface proteins, but without RNA needed for 
replication. Unable to replicate in cells, the VLP is not infectious. An Ebola 
VLP is produced by expression of Ebola VP40 and/or GP (53, 92, 95-97). 
The use of the Ebola VLP showed protection from lethal challenge of 
Ebola virus in rodents (92, 96) and in guinea pigs (78). The Ebola VLP can 
induce an inflammatory response, including the production of several 
inflammatory cytokines such as IL6, IL8, IL12, and TNFα (53). Moreover, 
the Ebola VLP is able to activate CD4+ and CD8+ T cells in vaccinated 
mice (92) and enhance the numbers of NK cells in their lymphoid tissues 
(94). Another study showed that the Ebola VLP can be uptaken by human 
dendritic cells (DCs) and induce them to upregulate the costimulatory 
molecules, major histocompatibility complex (MHC) class I and late DC 
maturation marker CD83 (8). These results confirmed that the Ebola VLP 
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effectively stimulates antigen-presenting cells and can enhance innate and 
adaptive immune response. 
The second type of viral-based vector studied for use as an Ebola 
vaccine is the Venezuelan equine encephalitis virus (VEE) replicon 
particle (VRP). In the replicon vector, the VEE structural genes are 
replaced with a gene of interest. When the replicons are introduced into 
cells, the replicons are restricted into a single cycle of replication because 
they lack the VEE structural proteins. Thus, they cannot assemble into 
particles and spread into uninfected cells. The VRP-expressed Ebola GP 
showed protection of BALB/C mice and two strains of guinea pigs from 
lethal Ebola infection (60). The VRP-expressed Ebola NP also protects 
mice against Ebola challenge by inducing Ab response against Ebola NP 
and MHC class I restricted cytotoxic T lymphocyte (CTL) response to 
Ebola NP. The results also showed that the passive transfer of serum-
contained antibodies specific to the Ebola NP cannot protect mice from 
challenge, but adoptive transfer of CTL specific to the Ebola NP can 
provide protection (99). These results support the VRP as a potential 
vaccine for Ebola because it can induce both humoral and cell-mediated 
immune response.  
 Another viral-based vector that was tested as an Ebola vaccine is 
the attenuated recombinant VSV vector. VSV vector-expressed Ebola GP 
completely protected monkeys from Ebola challenge after one 
intramuscular injection. The vaccine showed induction of humoral and 
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cellular immune response in the vaccinated monkeys (42). Recently, 
researchers have tried to develop an Ebola vaccine based on the human 
parainfluenza virus type 3 (HPIC3) (9, 104). Guinea pigs that were 
intranasally immunized with a single dose of the HPIC3-expressed Ebola 
GP showed immunogenic response and complete protection from lethal 
Ebola challenge. All of these viral-based vaccines showed promising data 
with respect to activation of both arms of the immune response and 
provided protection for animals from Ebola challenge. But the greatest 
concern about this type of vaccine is whether these viral vectors are really 
safe to be used in humans. 
From previous studies, we know that both humoral and cell-
mediated immune responses play important roles in protection against 
Ebola virus infection. Although the study of the Ebola VLP showed 
protection against Ebola challenge, serum transfer from Ebola VLP-
vaccinated mice did not protect the naïve mice (93). This demonstrates 
that the humoral immune response alone might not be enough for 
protection. Cell-mediated immune response also plays an important role in 
the protection against Ebola virus infection. Activation of these two arms of 
the immune system is vital for developing efficient Ebola vaccines and 
therapeutics. Many types of Ebola prophylaxis and treatments have been 
developed, but currently there are no approved vaccines or therapeutics 
against Ebola virus for human use. The new discovery of an Ebola 
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vaccine is still necessary. In this thesis, the immune complex is applied as 
a new strategy for Ebola vaccine development.  
Immune Complex 
The antigen-antibody immune complex is formed in vivo as a 
natural process completing a humoral immune response to an antigen. 
Generally, the immune complex (IC) is effectively engulfed and removed 
by mononuclear phagocytes (69). Previously, it has been shown that the 
protein antigen (Ag) contained within the IC is much more effectively 
processed and presented in the MHC molecule than free Ag by DCs in 
vitro (2, 68). DCs are the most potent antigen-presenting cells (APC) 
among all cell types, including macrophages and B cells. The uptake of 
the IC by cells occurs through two preferential receptors on the surface of 
APC, complement receptor (61, 103) and Fc receptor (FcR) (15, 35). The 
IC binds to the Fc receptor and mediates a variety of responses from 
phagocytosis to Ab-mediated cellular cytotoxicity. The internalization of 
the IC by the DC, mediated by FcγR, enhances the presentation of both 
MHC class I and MHC class II binding peptides derived from the antigen 
presented in the IC. This can lead to DC activation. Previous studies 
showed that the IC can mediate efficient priming of Th cell response after 
binding to the FcR on the APC (33). Moreover, the activation of DCs by 
the IC enables these cells to efficiently prime CD8+ cytotoxic T 
lymphocyte response both against an exogenously loaded peptide and 
against endogenously processed peptide from the Ag present in the IC 
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(68). Due to efficient CD4+ and CD8+ priming activity, the IC is a 
promising target for Ebola vaccine development. 
In addition to FcγR, the complement system is known to interact 
with the IC. Three pathways of complement activation have been 
described:  the classical pathway, the alternative pathway, and the lectin 
pathway (90, 91). Each pathway has its own activation and recognition 
mechanism, resulting in the formation of C3-convertase that cleaves the 
central complement component C3 into the fragments C3a and C3b. 
Binding of C3b enables clearance of pathogens and the IC, as well as the 
generation of the lytic membrane attack complex.  
C1q is one of the activator compounds of the classical complement 
pathway and plays an important role in the activation of the pathway and 
the clearance of the IC from the circulation (56, 72). C1q contains a 
collagen-like tail region to which serine protease C1r and C1s are bound, 
connected to a globular head region responsible for ligand binding. The 
C1q head can recognize a defined region within the CH2 domain of the 
Ag-complexed IgG molecule, thereby opsonizing the IC. C1q recognizes 
the complexed Ag with higher affinity than the free Ag. After binding to its 
ligand, C1q changes conformation, leading to the activation of its 
associated serine proteases, C1r and C1a. A study showed that mice 
deficient for C1q displayed a substantially reduced ability to present 
immune-complexed Ag to CD8+ T cells (84).  
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 Published evidence confirms that Ag presented in the IC can 
induce stronger humoral and cell-mediated immune responses than Ag 
alone. Thus, the IC is a target backbone used for vaccine development. 
Immune Complex Production in Plants 
A previous study showed the production of the IC in Nicotiana 
tabacum (12) and in that work, the complex was created by expressing 
tetanus toxin fragment C (TTFC) fused to the C-terminus of TTFC-specific 
monoclonal antibody. The IC without the addition of adjuvant proved to be 
highly immunogenic in mice, with IgG titer more than 10,000 times higher 
than the titer observed in mice immunized with antigen alone. It was also 
shown that the IC binds to a macrophage cell line, one of the APC, 
whereas the TTFC-specific monoclonal antibody does not. This indicates 
that antigen presented in the IC can enhance the binding to antigen-
presenting cells, leading to an increase in the process and antigen 
presentation via the MHC molecule. This result indicates that the IC 
expressed in plants are highly immunogenic in mice and can act as a self-
adjuvant. These studies point to possibilities for the development of a 
plant-based Ebola vaccine. 
Plant-produced Recombinant Protein 
Historically, bacteria were often used as protein expression 
systems because they are an inexpensive and convenient system. A 
major drawback to their use, however, is that they are incapable of many 
of the post-translational modifications necessary for the activity of 
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numerous mammalian proteins. Other protein expression systems include 
yeast cells, baculovirus-infected insect cells, mammalian cells, transgenic 
animals, and transgenic plants. Among these systems, plants have many 
advantages over the other systems. First, plants have a higher eukaryote 
protein synthesis pathway that is similar to the pathway in animal cells, but 
with minor differences in protein glycosylation (10). The post-translational 
modifications in plants are required for protein activity and suitable 
pharmacokinetics properties (30). Second, plants can produce 
recombinant proteins at high levels comparable to those produced in 
hybridomas (37). Third, using plants as the bioreactor avoids the 
contamination of expressed proteins with any human or animal pathogens. 
Importantly, plants are an inexpensive source to produce recombinant 
proteins. Mammalian cell cultivation requires sophisticated equipment and 
expensive media supplements, such as fetal bovine serum. It is estimated 
that protein production in plants is 10 to 50 times cheaper than production 
in E.coli (46). In addition to these advantages over other expression 
systems, plants have been shown to produce functional forms of complex 
mammalian proteins, including hemoglobin (16), collagen (73), and 
antibodies (37).  
 A wide variety of plant-based expression systems, such as tobacco, 
potato, tomato, and maize, are now available to produce recombinant 
proteins. Thus, there are many different candidate host species, and 
different systems. There is also a choice of several gene delivery and 
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expression mechanisms. The classical method is to create stably 
transgenic plants, which have a stable genetic modification either in the 
nuclear or chloroplast genomes. There are many advantages of this 
approach. The transformation is a fairly routine procedure in many plant 
species. A stable transgenic line can be used as a permanent genetic 
resource. Among the various plant systems, this method is the simplest to 
maintain and is the most scalable. Although the establishment of 
permanent transgenic plants has many advantages, the impediments 
include the long development time (required for transformation, 
regeneration, and analysis); the unpredictable impact of epigenetic events 
on transgenic expression; and concerns about transgene escape into the 
environment.  
An alternative strategy is transient gene expression, usually 
accomplished by vacuum infiltration of leaves with Agrobacterium 
tumefaciens:  transferred DNA (T-DNA) is transferred to a very high 
proportion of the cells, where it can integrate or remain as an episome, 
and in either case, will express high amounts of protein. This transient 
somatic transformation or agroinfection allows very high levels of 
expression without the uncertainties associated with the generation and 
propagation of transgenic plants.  
  To improve the protein expression level in transient expression, 
plant viral vectors can be applied. Plant viruses are very efficient 
pathogens, using very compact genomes to force host cells to produce 
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very large amounts of viral proteins. Consequently, plant viruses allow the 
rapid and convenient production of recombinant protein in plants. 
Compared with stable transformation, viral vectors are easier to 
manipulate, and recombinant proteins can be produced more quickly and 
in greater yield. Several types of RNA viruses have been used to create 
plant viral expression vectors, including tobacco mosaic virus (TMV), 
potato virus X (PVX), cowpea mosaic virus (CPMV), and alfalfa mosaic 
virus (AIMV) (107).  
Geminivirus 
Plant viral expression is not limited to RNA viruses; some plant 
DNA viruses also can be used. Geminiviruses are plant viruses containing 
a single-stranded circular DNA genome varying in size from 2.5 kilobases 
(kb) to 3.0 kb, depending on the virus. The genomic DNA is replicated in 
the nucleus of the host cell by a rolling circle replication mechanism, 
utilizing double-stranded DNA intermediates (58). There are four different 
genera— Mastrevirus, Curtovirus, Topovirus, and Begomovirus. 
Mastreviruses have a monopartite genome and infect both monocot plants 
(wheat dwarf virus, maize streak virus, and digitalia streak virus) and dicot 
plants (tobacco yellow dwarf virus and bean yellow dwarf virus). The 
genome of the Mastreviruses contains two intergenic regions—long 
intergenic region (LIR) and short intergenic region (SIR)—located at 
opposite sites of the viral genome. There are four proteins encoded by the 
genome: the movement protein (MP) and the capsid protein (CP) on the 
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viral-sense (V) strand, the Replication initiator (Rep) protein, and the RepA 
protein on the complementary-sense (C) strand. LIR and SIR are the only 
cis-elements required for replication of the genome. The LIR has bi-
directional promoter elements and a stem-loop structure that is essential 
for initiation of rolling-circle replication of the V-strand. The SIR is the 
origin of the C-strand synthesis and contains transcription termination 
signals. Rep is required for replication but it can be supplied in trans.  
Geminiviruses replicate DNA via a rolling-circle replication 
mechanism, where Rep is involved with nicking-closing activity (14). 
Initially, viral single-stranded DNA enters into the cells and is converted 
into a double-stranded DNA replicative form. The replicative form serves 
as the template for viral transcription as well as the template for further 
replication. The next stage is to generate more replicative form and is 
initiated by the viral Rep protein. Rep can nick the plus strand at a specific 
sequence and then covalently bind to the 5’ terminus. The 3’ –OH 
terminus is used as the primer for the synthesis of a nascent plus strand 
(47). The DNA synthesis is accomplished by host replication proteins. 
Completion of the nascent plus strand regenerates the origin of replication 
which is nicked by Rep protein again. This time, Rep protein acts as a 
terminase to release the displaced plus strand, which is simultaneously 
ligated to the circular form by the closing activity (48). In the process, Rep 
is transferred to the newly created 5’ terminus. The third stage, occurring 
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late in the replication cycle, is responsible for the accumulation of viral 
genomes for encapsidation (32).  
The geminiviral replicon system can be used to enhance foreign 
protein expression in plants. Previous studies demonstrated that the 
geminivector system produced recombinant proteins such as GUS protein 
(55), GFP protein (44), and Staphylococcus enterotoxin B in NT-1 cells 
(34). Moreover, the geminiviral replicon system can be used to express 
antibodies in plants (38). 
Plant-produced Glycoprotein 
More than one-half of all eukaryotic proteins, as well as one-third of 
the approved biopharmaceuticals, are glycoproteins. There are two types 
of glycosylation based on the method of carbohydrate attachment to the 
protein:  N-glycan links to the amide group of asparagine, and O-glycan 
bonds to the hydroxyl group of serine, threonine, hydroxylysine or 
hydroxyproline residues in the protein. Protein glycosylation occurs in the 
secretory pathway. N-glycosylation starts in the endoplasmic reticulum 
(ER), with the cotranslational or post-translational transfer of a preformed 
lipid-linked oligosaccharide onto the nascent polypeptide. In contrast, O-
glycans are synthesized by a stepwise transfer of monosaccharides on the 
folded protein in the ER and Golgi apparatus.  
 The biological activity of many therapeutic glycoproteins, such as 
antibodies, blood factors, and interferons, depends on their glycosylation 
pattern. This can explain why biopharmaceuticals are often produced in an 
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expression system with glycosylation capacities. The capacity of plants for 
glycosylation supports the use of plants as means of therapeutic 
production over that of E. coli. Unfortunately, plants are unable to produce 
human-type glycosylation patterns for biopharmaceuticals (21, 30); plant-
specific glycosylation is considered to be a limitation for the use of plant-
made pharmaceuticals in human therapy, although a previous study 
indicated that plant glycan is not immunogenic in mice (13). Plants 
synthesize a core complex N-glycan structure similar to that in mammalian 
cells, but the terminal residues are different. Plant N-glycans are much 
smaller, lack β1,4-galactose and sialic acid, and carry plant-specific β-1,2-
xylose and core α-1,3-fucose residues. Because plant β-1,2-
xylosyltransferase and α1,3-fucosyltransferase are responsible for the 
transfer of β-1,2-linked xylose and α-1,3-linked fucose residues to 
glycoprotein N-glycans, knockout plants with complete deficiencies of 
these two enzymes creates plants that have a human N-glycan pattern (7, 
66, 74, 75). 
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Dissertation Summary 
Previous studies showed that the IC activates humoral and cell-
mediated immune responses. Since evidence indicates that an effective 
Ebola vaccine should induce both types of the immune responses, it is 
feasible to use the IC as a candidate vaccine for Ebola virus. In this 
dissertation, the Ebola immune complex (EIC) produced in Nicotiana 
benthamiana was studied. The EIC was made by fusing the Ebola GP1 at 
the C-terminus of the heavy chain of the monoclonal antibody 6D8, which 
binds to an epitope that is close to the C-terminus of the Ebola GP1. 
When the GP1-heavy chain fusion was co-expressed with the light chain 
of mAb 6D8, the EIC was formed.  
The second chapter of this dissertation describes the transient 
expression of humanized Ebola immune complex (hEIC) in N. 
benthamiana. After the IC was expressed, it was purified by ammonium 
sulfate precipitation and protein G affinity chromatography. The purified 
protein was used to immunize mice and determine the immunological 
response. The result showed immunogenicity of the plant-expressed 
hEIC, although the level of anti-Ebola IgG was low. Moreover, the mice 
produced high levels of the antibody specific to human IgG. Our 
hypothesis was that the antibody backbone in the IC might affect the 
immunogenicity of the antigen in the IC. Therefore, when we used 
humanized antibody backbone in the IC to immunize the mice, the human 
IgG was highly immunogenic in mice.  
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In the third chapter, we tested this hypothesis by changing the EIC 
antibody backbone from human to mouse IgG. The mouse  monoclonal 
antibody 6D8 was produced by using the constant region from mAb 
278.02 (12), and the variable region genes for both the heavy chain and 
the light chain were plant-optimized and synthesized. The results in 
Chapter 3 indicated that the mouse Ebola immune complex (mEIC) was 
immunogenic in mice to a similar extent as the hEIC. Changing the 
antibody backbone to use the one that matches the host did not improve 
the immune response against the EIC. 
The fourth chapter presents the immunological study and challenge 
study of the EIC vaccine delivered with different adjuvants. The EIC was 
used to immunize mice with or without adjuvants. The immunized mice 
were then challenged with lethal Ebola virus to determine whether the EIC 
could protect the mice. The results showed that mice immunized with four 
doses of the EIC and the adjuvant polyinosinic-polycytidylic acid (PIC) 
were protected against the Ebola challenge. This validates the hypothesis 
that plant-produced EIC may be used as an effective vaccine against 
Ebola virus. 
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Chapter 2 
EXPRESSION OF AN IMMUNOGENIC EBOLA IMMUNE COMPLEX IN 
NICOTIANA BENTHAMIANA 
ABSTRACT 
Filoviruses (Ebola and Marburg viruses) cause severe and often 
fatal hemorrhagic fever in humans and non-human primates. The U.S. 
Centers for Disease Control (CDC) identify Ebola and Marburg viruses as 
“category A” pathogens (defined as posing a risk to national security as 
bioterrorism agents); this categorization has invigorated a search for 
vaccines that could prevent the disease. Because the use of such 
vaccines would be in the service of public health, the cost of production is 
an important component of their development. The use of plant 
biotechnology is one possible way to cost-effectively produce subunit 
vaccines. In this work, a geminiviral replicon system was used to produce 
an Ebola immune complex (EIC) in Nicotiana benthamiana. The Ebola 
glycoprotein (GP1) was fused at the C-terminus of the heavy chain of the 
humanized IgG monoclonal antibody 6D8, which specifically binds to a 
linear epitope on the GP1. Co-expression of the GP1-heavy chain fusion 
and the 6D8 light chain using a geminiviral vector in the leaves of 
Nicotiana benthamiana produced an assembled immunoglobulin, which 
was purified by ammonium sulfate precipitation and protein G affinity 
chromatography. The immune complex formation was confirmed by 
assays that showed that the recombinant protein bound to the 
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complement factor C1q. Size measurements of purified recombinant 
protein by dynamic light scattering and size exclusion chromatography 
also indicated complex formation. Subcutaneous immunization of BALB/C 
mice with the purified EIC resulted in anti-Ebola virus antibody production 
at levels comparable to those obtained with a GP1 virus-like particle. 
These results show excellent potential for a plant-expressed EIC as a 
human vaccine. 
INTRODUCTION 
Recombinant protein expression systems are widely used in the 
biotechnology industry to produce enzymes, protein hormones, 
monoclonal antibodies, and antigenic proteins for subunit vaccines. 
Currently available commercial products are produced by fermentation 
using bacterial suspensions or cultures of insect, yeast, or mammalian 
cells. Recently there has been substantial progress in the use of green 
plants as a platform for production of pharmaceutical proteins (2, 43). 
Advantages in using plants that facilitate industrial adaptation include 
rapid time frames for production of gram quantities of new proteins for 
preclinical testing, the ability of plants to produce large and complex 
proteins with correct processing and assembly into multi-subunit 
complexes, and recent advances in plant biotechnology allowing the 
production of glycoproteins with human-like glycosylation patterns (5, 10, 
24, 25, 46). In addition, cost advantages of plant-made pharmaceutical 
proteins relate to capital cost avoidance (plant production vs. 
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fermentation) for new manufacturing facilities. 
 Recombinant protein production in plants can be achieved utilizing 
two different systems: stable genetic transformation or transient gene 
expression. The establishment of stable transgenic plants is time-
consuming, with the major limitation being relatively low levels of protein 
expression (17, 38). For transient expression, the plant viral vectors can 
be used to amplify gene copy number, leading to much higher protein 
expression in comparison to stable transformation. Various types of RNA 
viruses have been used to create plant viral expression vectors, such as 
tobacco mosaic virus (TMV), potato virus X (PVX), cowpea mosaic virus 
(CPMV), and alfalfa mosaic virus (AIMV) (56). In an effort to improve the 
efficiency of the traditional viral vector, a deconstructed tobacco mosaic 
virus (TMV)-based system called magnICON was created (18, 19, 33). 
The magnICON vector system yielded excellent results with different 
proteins including enzymes, antibodies, antigens, cytokines, and 
hormones (17).  
 DNA viruses such as the geminiviruses can be used as plant viral 
vectors to express recombinant protein. Geminiviruses have a single-
stranded DNA genome that replicates in the nucleus of host cells by a 
rolling circle replication mechanism using a double-stranded DNA 
intermediate (20, 47). The viral replication initiation protein (Rep) initiates 
the replication cycle by binding to a specific viral DNA sequence in the 
long intergenic region (LIR) and cleaving it, which promotes rolling circle 
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replication mediated by host cell DNA polymerase and other factors. Rep 
then ligates the single-stranded DNA products to form a circular viral DNA 
(29). For recombinant protein expression, the geminiviral coat protein and 
movement protein can be replaced with the gene of interest. After Rep 
protein is expressed, the replicon containing the gene of interest is 
amplified, and the double-stranded DNA intermediates act as transcription 
templates, leading to high amounts of mRNA and subsequent 
recombinant protein (24, 25, 37). 
Ebola virus, the causative agent of Ebola hemorrhagic fever, is a 
negative sense, single-stranded RNA virus belonging to family Filoviridae. 
The shape of the virus is filamentous in form and approximately 80 nm in 
diameter, but it demonstrates no uniform length (11). There are four 
distinct species of Ebola virus: Zaire, Sudan, Ivory Coast, and Reston, 
with the Zaire Ebola virus causing the highest mortality rate among all 
Ebola viruses, up to 90% (52). Currently, there are no vaccines or antiviral 
drugs approved for prevention or treatment of this disease in humans. 
However, there are some new vaccine candidates, which have 
demonstrated protection in nonhuman primates against lethal challenge 
with Ebola virus, including Ebola Venezuelan equine encephalitis virus 
replicon particles (VRP) (39), Ebola virus-like particle (51), recombinant 
vesicular stomatitis virus-based Ebola vaccine (14, 15, 40), adenovirus-
based vaccine (42) and a prime-boost strategy with DNA encoding 
glycoprotein of the Zaire strain followed with recombinant adenovirus 
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encoding the same antigen (22, 49). Moreover, a DNA vaccine encoding 
for the Ebola glycoprotein (GP) has been shown to be both safe and 
immunogenic in humans (34). 
Ebola GP is a glycoprotein containing both N- and O-linked 
carbohydrate (12, 13). GP is a type I transmembrane protein that forms 
homotrimers, which create a spike on the viral envelope (31, 54). It 
mediates viral binding and entry into host cell (30). GP consists of two 
subunits, the extracellular GP1 and the membrane-anchored GP2, linked 
by disulfide bonds (32, 44). GP1 is responsible for receptor binding, and 
GP2 mediates membrane fusion. Transient expression of GP in cultured 
mammalian cells causes cytopathic effects including cell rounding and 
detachment (6, 45). GP can down-regulate several cell surface molecules 
such as major histocompatibility complex class I (48) and integrin (45). 
Since Ebola GP is the protein that mediates infection and is the major 
antigen (53), it is a critical target for vaccine development. Ebola GP, or 
segments thereof, can be expressed in recombinant systems such as E. 
coli (8), insect cells (36, 55), and mammalian cells (35). However, these 
systems are not optimal, and in order to reduce its toxicity on the host cell, 
GP1 expression in mammalian cells was regulated by an ecdysone 
inducible system (35). 
Recombinant immune complexes were originally expressed in 
tobacco plants via fusion of tetanus toxin fragment C (TTFC) to the heavy 
chain of a TTFC-binding IgG and co-expression with its light chain (7). The 
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TTFC immune complexes were shown to bind to C1q, Fc receptor gamma 
RIIa (FcγRIIa), and antigen-presenting cells. Mice immunized with the 
recombinant TTFC immune complexes showed much higher antibody 
titers than those immunized with TTFC alone. This study demonstrated 
the recombinant immune complex as a strong vaccine candidate and led 
us to pursue a similar strategy with Ebola GP1. 
In this study, we used the geminiviral replicon system derived from 
bean yellow dwarf virus (24, 25, 37) to produce the EIC in Nicotiana 
benthamiana. We fused Ebola GP1 at the C-terminus of the heavy chain 
of the humanized monoclonal antibody (mAb) 6D8  (25), which specifically 
binds to a linear epitope on GP1. When the fusion protein was co-
expressed with the light chain of mAb 6D8, IgG molecules assembled, 
leading to IC formation. The EIC were expressed, purified, and used to 
immunize mice, showing that the plant-expressed EIC represent a viable 
vaccine candidate for humans. 
MATERIALS AND METHODS 
Design of the construct for producing the Ebola immune complex 
The geminiviral vector pBYK3R was previously described (25). We 
designed a plant-optimized DNA sequence encoding the Ebola GP1 
based upon the GenBank Accession AY354458, using codons that are 
preferred in tobacco, and removing spurious mRNA processing signals 
(16). The designed sequence is deposited in the GenBank (Accession 
HM136775). The GP1 coding sequence was fused via a (G4S)3 linker to 
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the C-terminus of a gene encoding the humanized monoclonal antibody 
6D8 H2 (25).The linker was added to the 3’ end, and an XbaI site was 
created at the 5’ end of the 6D8-H2 gene by end-tailoring PCR using the 
primers H2-Xba-F (5’-GGTCTAGAACaATGGGATGGTCTTGCATC) and 
6D8H2-G4S-Bam (5’-
GGGGATCCACCTCCGCCTGAACCGCCTCCACCTGATCCGCCACCTC
CTTTACCCGGAGACAAGGAGAG). A BamHI site was created at the 5’ 
end of the GP1 gene by PCR using the primer GP1-Bam (5’-
GGGGATCCATCCCACTTGGAGTTATTC), and the 6D8-H2-((G4S)3 and 
GP1 genes fused via the BamHI site. The 6D8-H2-((G4S)3-GP1 fusion was 
inserted into the geminiviral vector pBYR1 (a derivative of pBYK3R that 
has unique XbaI, KpnI, and SacI sites for insert cloning) via XbaI and SacI 
sites. The hexapeptide SEKDEL was added to the C-terminus of the GP1 
sequence by end-tailoring with the reverse primer GP1-SEKDEL-Kpn-R 
(5’- 
CCGGTACCTTAAAGCTCATCCTTCTCTGAACGCCTAGTTCTTCGTCC) 
and the modified gene inserted into pBYR1 via XbaI and KpnI sites. 
H2GP1 is inserted in the geminivector between the LIR and SIR. The light 
chain of  mAb 6D8 or K3 is expressed in another geminivector with Rep 
protein. When H2GP1 and K3 were expressed in tobacco, the IC was 
formed because the variable region of mAb 6D8 can specifically bind to 
the 6D8 epitope of GP1. The dual replicon vector pBYRH2GP1kdK3, 
containing the fused replicons from pBYH2GP1kd and pBYK3R, was 
  45 
constructed by ligating three fragments: pBY-HL(6D8).R (25) XbaI-SacI, 
pBYH2GP1kd/XbaI-HindIII, and pBYH2GP1kd/HindIII-SacI. 
Ebola GP1 alone was expressed by co-infiltrating with 
pBYR6HGP1kd and pPSP19. pBYR6HGP1kd was constructed by fusing 
the GP1-SEKDEL coding sequence from pBYH2GP1kd (BamHI-SacI) with 
the soybean vspA N-terminal signal peptide (NcoI-BamHI) from pBTI201.4 
(26), which had been modified by addition of a 5’ sequence to encode the 
amino acids M-A-S-S and the 3’ sequence encoding a 6-His tag, by PCR 
using the mutagenic primers aS-MASS (5’-
GATCCATGGCTTCCTCTAAGGTCCTTGTTTTCTTCG) and 6H-Bam-R 
(5’- CGGGGATCCgTGaTGATGGTGATGGTGTC). The two fragments 
were ligated with pBYR1 (digested NcoI-SacI) to make pBYR6HGP1kd. 
GFP was expressed by using pBYGFP.R (24), co-infiltrating with pPSp19. 
Plant inoculation and protein expression 
Nicotiana benthamiana plants were inoculated with Agrobacterium 
by needle infiltration on the lower surface of leaves. The agroinfiltration 
procedure was performed as previously described (24). For geminivector 
constructs, final OD600 is 0.25. Plants were maintained in a growth 
chamber. The leaves were harvested on day 2, 4, 6, and 8 after infiltration 
for expression time-course experiments. For other experiments, the leaves 
were harvested on day 4 after infiltration. Soluble proteins were extracted 
by grinding the leaves with the Fastprep (Bio101) machine in 1ml of 
extraction buffer (phosphate-buffered saline (PBS) pH7.5, leupeptin, and 
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0.1% Tween-20) per 0.1mg of leaves. After centrifugation at 13,000 rpm 
for 5 min, the supernatant was retained for subsequent analysis by ELISA 
and Western blot.  
Sandwich ELISA protocol for Ebola immune complex quantification 
The EIC in the plant extract was quantified by ELISA. Goat anti-
human IgG was diluted 1:1000 in phosphate-buffered saline (PBS pH7.5; 
50µl per well) and was bound to 96-well polyvinylchrolide microtiter plates 
overnight at 4°C. Each plate was blocked with 5% skim mil k in PBS for 2 
hours at 37°C. After washing the wells one time with P BS containing 
0.05% Tween 20 (PBST), samples (50µl per well) diluted in 1% skim milk 
in PBST were added to the wells and incubated 1 hour at 37°C. The wells 
were washed three times with PBST and incubated with goat anti-human 
kappa-horseradish peroxidase (HRP) conjugate diluted 1:4000 in 1% skim 
milk in PBST for 1 hour at 37°C. Plates were develop ed with TMB 
substrate (Pierce, Rockford, IL) for 5 min at 23°C. Th e reaction was ended 
by addition of an equal volume of 1M H2SO4, and the absorbance was 
read at 450 nm. 
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SDS-PAGE and Western blot 
Plant protein crude extracts and human IgG were denatured by 
boiling in SDS-PAGE sample buffer and separated on 4–15% gradient 
polyacrylamide gels. Proteins were either visualized by Coomassie blue 
staining or electrophoretically transferred to a polyvinlidene difluoride 
(PVDF) membrane (Amersham, NJ). To detect the human heavy chain, 
the membrane was probed with goat anti-human IgG-HRP conjugate  
(Southern Biotech, AL) diluted at 1:5000 in 1% skim milk in PBST. To 
detect the human light chain, the membrane was probed with goat anti-
human kappa-HRP conjugate (Southern Biotech, AL), diluted at 1:10000 
in 1% skim milk in PBST. To detect Ebola GP1, the membrane was 
incubated with mouse anti-6D8 (antibody against the linear 6D8 epitope in 
GP1) or mouse anti-13C6 (antibody against a conformational epitope) 
diluted 1:10000 in 1% skim milk in PBST and goat anti-mouse IgG-HRP 
conjugate diluted 1:10000 in 1% skim milk in PBST. The membranes were 
developed by chemiluminescence using ECL plus detection reagent 
(Amersham, NJ).  
C1q binding assay 
50µl of 7.5µg/ml human complement C1q in PBS was coated on 
the wells of a polyvinylchrolide microtiter plate overnight at 4°C. After 
washing with PBST for 2 times, the plate was blocked with 5% skim milk in 
PBST for 2 hours at 37°C. The plate was washed with PB ST 1 time. Plant 
extracts containing 25ng equivalent amounts of human IgG from leaves 
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expressing the mAb 6D8 or EIC, (as determined by ELISA), were serially 
diluted, added into the plate, and incubated overnight at 4°C. After 
washing for 3 times with PBST, the plate was incubated with 1:4,000 goat 
anti-human kappa-HRP in 1% skim milk in PBST for 1 hour at 37°C. The 
plate was developed with TMB substrate and read OD450.  
Protein purification 
Infiltrated tobacco leaves were homogenized by using a blender 
with extraction buffer (PBS + protease inhibitor tablet from Sigma, MO). 
Crude extract was filtered through Miracloth and centrifuged at 17700g for 
15 min. Ammonium sulfate was added into the supernatant to 35% 
saturation (194g/l of solution) and mixed with a stirrer at 4oC for 1 hour. 
The solution was centrifuged at 17700g for 15 min, and the pellet was 
discarded. Then, ammonium sulfate was added to the supernatant to 60% 
saturation (151g/l of the solution) and mixed with a stirrer at 4oC for 1 
hour. The solution was centrifuged at 17700g for 15 min, and the pellet 
was dissolved with the extraction buffer. The solution was filtered with a 
0.2-micron filter, and Protein G beads (Pierce, Rockford, IL) was added 
into the filtered solution. The protein extract and the Protein G beads were 
rotated at 4oC for 1 hour, and then loaded into the column, and the resin 
beads were allowed to settle. The protein G column was washed with 
PBS, pH7.5, and eluted with 50mM citric acid, pH2.5. After the protein was 
eluted from the column, 1M Tris-base was added to neutralize to a final 
pH of 7.5. The purified protein was filtered through a 0.2 micron filter and 
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concentrated with Amicon ultra-4 Centrifugal Filter Units-30kDa (Millipore, 
MA). 
Estimation of complex size by dynamic light scattering 
The diameter size was measured by Dynamic Light Scattering 
using a Zetasizer Nano-ZS instrument (Malvern Instruments, UK). The 
purified plant-made EIC, purified plant-made mAb 6D8, and human IgG 
(Southern Biotech, AL) were diluted in PBS to 0.1mg/ml concentration and 
added into the disposable polystyrene cuvette for Zetasizer measurement.  
Size exclusion chromatography 
A sample volume of 20µl was loaded onto a BioSep SEC-S4000 
column, 600X7.8 mm (Phenomenex, CA). The proteins were eluted with 
PBS, pH 7.3, at a 1ml/min flow rate. A chromatogram was recorded, 
measuring the UV absorbance at 280 nm. Bovine thyroglobulin (Sigma, 
MO) and mouse IgG (Southern Biotech, AL) were used as protein 
markers. 
Mice immunization 
Female BALB/C mice were subcutaneously immunized with the 
purified EIC from tobacco leaves. The EIC (10µg dosage, equivalent to 
~5µg of Ebola GP1) was injected into the mice. VRP-GP1 (1.6 x 108 
replicons per mouse) was used as the positive control (provided by 
William Pratt, USAMRIID), and PBS was used as the negative control. 
The mice were immunized on days 0, 21, 42, and 63. Individual 
  50 
preimmune blood samples were collected before the first immunization, on 
day 0. Blood samples were obtained 3 weeks after the last immunization.  
Serum antibody analysis 
The specific serum IgG response was determined by end point titer 
ELISA. Polyvinyl chloride 96-well ELISA plates were coated with 50µl of 
irradiated Ebola virus (provided by John Dye, USAMRIID) diluted 1:1000 
in PBS and incubated at 4°C overnight. Plates were bl ocked with 5% skim 
milk in PBST at 23°C for 2 hours. Subsequently, the pl ates were incubated 
with the serum diluted in 1% skim milk in PBST for 1 hour at 37°C and 
then HRP-conjugated goat anti-mouse IgG for 1 hour at 37°C. The plates 
were developed with TMB substrate and read OD450. Endpoint titer was 
reported as the reciprocal of the highest dilution that had an absorbance 
value ≥ 0.02 (two times the OD value for pre-immune serum) above the 
background (absorbance of the well lacking the serum). 
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RESULTS 
Transient expression of the recombinant Ebola immune complex in 
leaves 
We produced the EIC by co-expression of a heavy chain-GP1 
fusion protein (H2GP1) with the light chain (K3). We examined EIC 
expression in N. benthamiana leaves using geminiviral replicons. The 
expression of the viral Rep protein (C1/C2 gene) is required for 
amplification of the replicon (29). The Rep cassette is contained in the 
complimentary sense orientation of the light chain vector pBYK3R (Fig. 1). 
The expression cassettes, driven by the dual-enhancer CaMV 35S 
promoter, are placed between the long intergenic region (LIR) and the 
short intergenic region (SIR) in the viral-sense orientation, replacing the 
viral movement and coat protein genes. In the case of dual replicon vector 
pBYRH2GP1kdK3, the heavy chain-GP1 fusion and light chain cassettes 
are placed within different replicons oriented in tandem. Ebola GP1 protein 
was expressed in plants by using pBYR6HGP1kd, which has a 6His tag at 
the N-terminus (Fig. 1). We also co-expressed the gene silencing inhibitor 
p19 from the tomato bushy stunt virus using the non-replicating 
expression vector pPSp19. 
Ebola GP1 expressed from pBYR6HGP1kd produced strong 
necrosis in leaves. However, fusing the GP1 to the mAb 6D8 reduced the 
toxicity of the GP1 to the plant (Fig. 2). We compared the protein 
expression levels using pBYK3R co-delivered with pBYH2GP1 or 
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pBYH2GP1kd (encoding H2GP1 with SEKDEL at C-terminus), and 
extracting four days after agroinfiltration. We assayed by ELISA to 
measure human IgG and found that the SEKDEL construct yielded ~3-fold 
higher expression than the construct withouth SEKDEL (Fig. 3a). Thus, we 
used the SEKDEL construct in the dual replicon vector pBYRH2GP1kdK3, 
which provided somewhat higher expression than co-delivery of the two 
separate vectors, up to ~50µg IgG per g leaf mass (Fig. 3a). Therefore, 
we used pBYRH2GP1kdK3+p19 in subsequent experiments to produce 
and characterize the EIC. A time course of the EIC expression on different 
days after infiltration showed that the optimal harvest time was 4 days 
after infiltration (Fig. 3b). 
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Fig. 1. Schematic representation of the T-DNA region of the vectors used 
in this study.  
35S/TEV5’: CaMV 35S promoter with tobacco etch virus 5’UTR; VSP3’: 
soybean vspB gene 3’ element, 35S/TMV5’: CaMV 35S promoter with 
tobacco mosaic virus 5’UTR; VSP3’: soybean vspB gene 3’ element, 
rbcS3’: tobacco Rubisco small subunit gene 3’ element, NPTII: expression 
cassette encoding nptII gene for kanamycin resistance (yellow box), LIR 
(red box): long intergenic region of BeYDV genome, SIR (blue box): short 
intergenic region of BeYDV genome, C2/C1 : BeYDV ORFs C1 and C2 
which encode for the replication initiation proteins (Rep) and RepA, LB, 
and RB : the left and right borders of the T-DNA region.  
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Fig. 2. Typical phenotype of leaves on day 5 expressing the mAb 6D8 (1), 
Ebola GP1 (2), Ebola immune complex (EIC) (3), and GFP (4).  
N. benthamiana leaves were co-infiltrated with pBYH2kdel+pBYK3R+p19 
for the mAb 6D8 expression  (1), pBYR6HGP1kdel+p19 for Ebola GP1 
expression (2), pBYRH2GP1kdelK3+p19 for EIC expression (3), and 
pBYGFP.R+p19 for GFP expression (4) at a final OD600 = 0.25. The 
leaves were photographed on day 5 after infiltration. 
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Fig. 3. Expression of the EIC in N. benthamiana plants.  
A. Protein expression of the EIC compared among different constructs. N. 
benthamiana leaves were co-infiltrated with pBYH2GP1+pBYK3R+p19, 
pBYH2GP1kdel+pBYK3R+p19, and pBYRH2GP1kdelK3R+p19 at a final 
OD600=0.25. The leaves were harvested 4 days after infiltration and 
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extracted to quantify IgG (Experimental Procedures) using ELISA. B. 
Protein expression levels at different times after agroinfiltration using 
pBYRH2GP1kdK3 with pPSp19. The leaves were harvested on day 2, 4, 
6, and 8 days post-infiltration (DPI). Data are means +SD of samples from 
three independent infiltration experiments. 
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C1q binding assay  
C1q is a protein component of the complement cascade of the 
mammalian innate immune system. C1q binds to the IC with a higher 
affinity than to antibody alone (28). We used the C1q binding assay to 
confirm the IC formation in plant leaf extracts. Varying dilutions of leaf 
extracts expressing the mAb 6D8 (pBYH2kd+pBYK3R) or the EIC 
(pBYRH2GPkdK3) at equivalent IgG concentrations were incubated with 
C1q, which was immobilized on the microtiter plate wells. The data (Fig. 4) 
show that the EIC-expressing leaf extracts produced substantially higher 
OD signals than the mAb alone, which is consistent with previous 
observations (28). These data indicate the formation of the IC when the 
EIC was produced in N. benthamiana. 
Purification and characterization of the Ebola immune complex 
To purify the IC, we used ammonium sulfate precipitation and 
protein G affinity chromatography. These two steps removed the great 
majority of the endogenous leaf proteins, including the major plant protein 
Rubisco, as shown by reducing SDS-PAGE (Fig. 5, lane 3). We estimate 
that the EIC preparation was ~90% pure, based on visual inspection 
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Fig. 4. C1q binding of crude plant extracts.  
Crude extracts were quantified for the amount of IgG by ELISA. Crude 
extracts were diluted to an IgG concentration of 100ng/ml, and then serial 
2-fold dilutions were made. The dilutions of crude extracts were added to 
wells containing immobilized C1q. Detection with HRP-labeled goat anti-
human IgG yielded OD450 measurements. Data are means +SD of 
samples from three independent infiltration experiments. 
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Fig. 5. Purification of the EIC from N. benthamiana leaves. 
Infiltrated leaves were extracted, and the EIC was purified and analyzed 
by SDS-PAGE under reducing conditions. Lane 1: Protein ladder; lane 2: 
clarified crude leaf extract; lane 3: leaf proteins removed by 35% 
ammonium sulfate precipitation; lane 4: 60% ammonium sulfate 
precipitate resuspended for Protein G chromatography; lane 5: 100% 
ammonium sulfate precipitate; lane 6: protein G flow-through fraction; 
lanes 7-10: sequential elution fractions from Protein G chromatography. 
The black arrow indicates rbcL protein. 
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of the Coomassie-stained gels (lane 8 in Fig. 5 and Fig. 6b). We observed 
that the EIC extracted directly from leaves in SDS sample buffer (reducing 
conditions) displayed a single band at 130kDa when probed with anti-
heavy chain (Fig. 6a). The purified EIC examined on Coomassie-stained 
gels comprised five different protein species with apparent molecular 
weights of 130, 110, 55, 50, and 25kDa (Fig. 6b). The Western blot 
showed that anti-human heavy chain bound to the largest four of the five 
species (Fig.6c), whereas the anti-GP1 linear epitope 6D8 (53) bound to 
only the 130kDa protein (Fig. 6e). Anti-human kappa chain antibody 
bound to the protein at 25kDa (Fig. 6d), which is the expected size of the 
kappa chain. A gel run under non-reducing conditions and probed with 
monoclonal antibody 13C6, which binds to a conformational epitope (53), 
showed a signal at high molecular mass (Fig. 6f), which is consistent with 
a fully assembled immunoglobulin structure. This confirmed the correct 
folding of GP1 in the H2-GP1 fusion protein expressed in N. benthamiana. 
The presence of multiple protein species that contain the heavy chain 
sequence (Fig. 6c) indicates proteolytic degradation during extraction and 
purification, since the smaller bands were not present when leaves were 
extracted directly in SDS sample buffer (Fig. 6a). Nonetheless, we 
conclude that the full length EIC is assembled in planta and the GP1 
showed correct folding. 
  
  61 
 
Fig. 6. Western blotting of the EIC.  
(a) Crude extract from N. benthamiana leaf agroinfiltrated with 
pBYH2GP1kdel, pBYK3R, and pPS19. The 100mg leaf sample was 
harvested 4 dpi and extracted with 500µl SDS sample buffer containing 
100mM dithiothreitol (DTT), and 20µl of the extract was loaded onto the 
gel. The Western blot was probed with an anti-human IgG heavy chain. (b-
f) Purified EIC from leaves agroinfiltrated with pBYH2GP1kdelK3 and 
pPS19:  (b) Coomassie-stained SDS-PAGE reducing gel; (c) Reducing 
Western blot detected with anti-human IgG heavy chain; (d) Reducing 
Western blot detected with anti-human kappa chain; (e) Reducing 
Western blot detected with anti-linear epitope mAb 6D8; (f) Non-reducing 
Western blot detected with anti-conformational epitope 13C6. 
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Molecular sizing of the EIC 
We assessed the diameter size of the purified EIC preparation 
using a Zetasizer Nano-ZS instrument (Malvern Instruments, UK), which 
measures the hydrodynamic diameter using dynamic light scattering. For 
these measurements, the purified EIC, the plant-made mAb 6D8, and 
human IgG (SouthernBiotech, AL) were diluted in PBS, pH7.5, to a 
concentration of 0.1mg/ml. The data shows that the average diameter of 
the EIC was ~20nm (Fig. 7), whereas the plant-made mAb 6D8  and 
standard human IgG were both ~10nm. The diameter of the antibody 
standard measured by Malvern Instruments was also 10nm (57), which 
was consistent with our result. Samples were also tested at a lower 
concentration of 10µg/ml, with the same results (data not shown). 
Moreover, size exclusion chromatography was used to confirm the 
complex formation. The mouse IgG and plant-made mAb 6D8 (150 kDa) 
eluted at 18 min and bovine thyroglobulin (669 kDa) eluted at 15 min (Fig. 
8). The EIC eluted over a broad region but had peaks at 11 min and 15–
16 min. Therefore, the size of the EIC eluted at 11 min exceeds 669 kDa, 
which suggests there are more than two molecules in the complex (one 
molecule is ~310 kDa). The peak at 15–16 min probably represents the 
dimer, and material eluting between 11–15 min may indicate larger 
oligomers.  
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Fig. 7. The size measurement confirmed the complex formation. 
The hydrodynamic diameter of the EIC or mAb 6D8 was determined by 
dynamic light scattering using a Zetasizer Nano-ZS instrument (Malvern 
Instruments, UK). The abscissa indicates the diameter in nm, and the 
ordinate indicates the relative number of molecules at that size, comparing 
human IgG, plant-expressed mAb 6D8 and plant-expressed EIC.  
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Fig. 8. The size exclusion chromatography confirmed the complex 
formation. 
Size exclusion chromatography was used to determine the size of the IC. 
The EIC was loaded onto a BioSep SEC-S4000 column (Phenomenex, 
CA) and eluted with PBS, pH7.3. The elution time in min is shown on the 
abscissa, and the A280 was continuously monitored (colored curves). 
Bovine thyroglobulin (Sigma, MO), mouse IgG (SouthernBiotech, AL), and 
plant-expressed mAb 6D8 were used as protein markers. 
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Immunization study 
To examine the immunogenicity of the plant-produced EIC, we 
immunized mice by subcutaneous injection on days 0, 21, 42, 63, with 
10µg purified EIC (measured as IgG equivalent). We used VRP-GP1 
(provided by John Dye, USAMRIID) as the positive control (39). Serum 
antibody responses were evaluated by ELISA using the irradiated Ebola 
virus as the capture antigen. Three weeks after the last dose, a geometric 
mean titer (GMT) antibody level in the plant-made EIC group was 
comparable to the VRP-GP1 group (Fig. 9). A placebo PBS-immunized 
group showed no anti-Ebola response and was arbitrarily placed at a GMT 
value of 1.0. These results indicate that plant-made EIC is immunogenic in 
mice to an extent comparable to VRP-GP1. It should be noted that VRP-
GP1 is an alphavirus-based particle and contains a RNA genome that 
undergoes a single round of replication in the host dendritic cells and 
macrophages (39). 
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Fig. 9. Anti-Ebola IgG responses in mice immunized with the EIC.  
Four groups of seven mice each were immunized subcutaneously with the 
EIC, VRP-GP1, or PBS. The immunizations were given on days 0, 21, 42, 
and 63. The serum was collected on day 84 and assayed for anti-Ebola 
IgG by ELISA, using gamma-irradiated Ebola virus as the capture antigen. 
The data are presented as Geometric Mean Titer (GMT) + 1SD for each 
group of mice. 
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DISCUSSION 
In this work, N. benthamiana plants were used as a bioreactor for 
the geminiviral replicon system to produce the EIC. The geminiviral 
replicon system has been used for plant production of several 
recombinant proteins, including GUS protein (37), GFP (27), 
staphylococcal enterotoxin (21), and capsid proteins of hepatitis B and 
Norwalk viruses (24). The system was also shown to produce antibody 
which is efficiently assembled and retains specific antigen binding 
properties (25). In this study, the geminiviral replicon system was used to 
produce a GP1-heavy chain fusion protein, which is approximately 
130kDa. The viral Rep protein can be supplied either in trans (37) or in the 
geminiviral vector with the gene of interest (24, 25). In this work, we 
demonstrate higher protein expression in a single vector system, using 
pBYRH2GP1kdelK3, than by co-delivery of two separate geminiviral 
replicons for the H and K chains (Fig. 3). Comparison of the constructs 
with or without the ER retention signal SEKDEL showed substantially 
higher expression with those containing SEKDEL. However, there may yet 
be potential to enhance the yield by optimizing the concentration of 
Agrobacterium in the infiltration, or by inclusion of the p19 expression 
cassette in pBYRH2GP1kdelK3 in order to avoid the use of two 
Agrobacterium strains for plant inoculation.  
The IC resulted from the expression of a fusion protein in which the 
antigen GP1 was linked to the heavy chain of the mAb 6D8 and co-
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expressed with the 6D8 light chain (K3). When the heavy and light chains 
assemble, the IC can be formed when the 6D8 antigen-combining sites at 
the N-termini encounter the GP1 6D8 epitope near the C-terminus of 
another molecule; this process is diagrammatically described in Fig. 10. 
ICs have several immunological functions, including C1q binding and Fcγ 
receptor binding, which enhance ability of the antigen to be taken up by 
antigen-presenting cells (3, 9, 23). Previous studies also demonstrated the 
binding of IC via the Fc receptor to DC induced DC maturation and 
promoted the efficient presentation of peptides on major histocompatibility 
complex classes I and II (4, 41). The enhanced endocytosis, the improved 
antigen presentation, and thereby the enhanced T cell activation may 
create the potential for ICs to be used as effective self-adjuvanting 
vaccines. C1q is a member of the complement cascade, which enhances 
the ability of the immune system to clear pathogens. It is known to bind to 
ICs with higher affinity than monomeric IgG (28). In this study, we 
demonstrated that the EIC binds to C1q significantly better than to the 
antibody alone. Moreover, the EIC particle size measured by dynamic light 
scattering indicated IC formation. The diameters of standard human IgG 
and plant-derived mAb 6D8 were measured at 10nm, which is similar to 
that reported for IgG by Malvern Instruments, UK (57). The EIC presented 
a diameter of 20nm, which strongly suggests the formation of the IC.  
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Fig. 10. Diagram illustrating the possible structure of the recombinant IgG 
and its assembly to form the EIC.  
At left, the 6D8 H2-GP1 fusion protein (blue H2 chain, green GP1) is 
assembled with the light chain (red) to form a chimeric IgG-GP1. The 6D8 
epitope on GP1 is shown as a red star. The epitope binding site at the top 
of the molecule can bind to the 6D8 eptiope displayed on other chimeric 
molecules, which results in complex assembly (middle, with the IgG 
component shown in purple). The complement component C1q can bind 
to the Fc region of IgG molecules that are bound to antigen (right). 
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Although the structure of Ebola GP1 is unknown, it is reasonable that the 
20nm-diameter EIC would accommodate at least four Ag-Ab fusion 
molecules. 
After purification with the protein G affinity chromatography, the 
material showed five protein species when analyzed under reducing 
conditions and stained with Coomassie blue dye (Fig. 5, bands at 130, 
110, 55, 50, and 25kDa), which indicate proteolytic cleavages in the fusion 
protein. The calculated approximate size of the full-length glycosylated 
GP1-heavy chain fusion is ~130kDa, equivalent to the largest band 
observed. Based on the amino acid sequence, the H2-GP1 fusion protein 
is expected to be ~100kDa. However, because the GP1 sequence 
contains 15 potential N-glycosylation sites that may be differentially 
utilized, the molecular mass could increase by up to ~30kDa. Thus, it is 
possible that the 110kDa protein represents a glycosylation variant, but it 
may also represent a fragment resulting from proteolysis at a site proximal 
to the GP1 C-terminus. The presence of the H-chain species (indicated by 
the positive reaction in Western blots, Fig. 6) at 55 and 50kDa suggests 
that some proteolytic degradation of the H2-GP1 occurred during the 
purification process, despite the use of protease inhibitors. Since 
extraction of leaves directly in reducing SDS sample buffer yielded only 
the 130kDa species (Fig. 6a), the full length fusion protein was stable in 
planta, and any degradation occurred only after extraction and processing 
under non-denaturing conditions. We observed a direct relationship 
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between the extent of degradation in crude extracts and the time they 
were kept at 4˚C (data not shown), which further supports the idea of post-
extraction instability. Thus, there is potential to increase yields of the EIC 
by the use of more appropriate protease inhibitors and by decreasing the 
processing time involved in purification. 
It is important to note that the GP1 protein folded correctly to 
produce authentic antigen. Western blotting with the mAb 13C6, which 
recognizes a conformational epitope of the Ebola GP1 (53), showed a 
signal at the expected size under non-reducing conditions (Fig. 6f). This 
observation indicates that the plant-expressed Ebola GP1 is folded 
correctly when assembled into a high molecular weight IgG complex. 
A further indication that the EIC contains the authentic GP1 antigen 
is provided by the mouse immunization data. When the EIC was delivered 
subcutaneously to the mice, it elicited antibodies (Fig. 9) that were specific 
to the whole Ebola virus. The antibody titers in the mice immunized with 
the EIC were comparable to those achieved using the VRP-GP1 positive 
control, which showed complete protection of the mice and guinea pigs 
from an Ebola virus challenge (39). Since VRP-GP1 is an alphavirus 
vector, it undergoes limited replication in antigen-presenting cells of the 
immunized host, thus creating a viral replicon RNA that can act as a 
powerful adjuvant through Toll-like receptor signaling (1). Thus, the finding 
that plant-derived EIC produced Ab responses comparable to those 
obtained with the VRP control is a significant observation that indicates 
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strong potential for the efficacy of an EIC vaccine. However, the level of 
Ebola-specific antibody might not correlate with the viral neutralizing 
activity and protective efficacy. These issues will be addressed in future 
studies. 
Our results are consistent with those of a previous study (7), which 
showed that a TTFC immune complex produced from Nicotiana tabacum 
enhanced immune response and acted as a “self-adjuvant” when used to 
immunize mice. In that study, a mouse IgG was fused with TTFC, and the 
resulting TTFC immune complexes were found to bind to mouse dendritic 
cells and induce significantly higher anti-TTFC IgG in mice compared to 
that induced by TTFC antigen alone. We detected substantial levels of 
antibody against human IgG in the serum of our immunized mice (data not 
shown). This result is not surprising, since we used the humanized  
antibody 6D8 in the IC, in order to use the EIC as a vaccine in humans. 
Therefore, it is possible that the anti-human IgG responses in the mice 
interfered with optimal anti-GP1 immune responses. We predict that use 
of the EIC in humans will induce a stronger anti-Ebola immune response, 
due to the potential for targeting the GP1 to antigen-presenting cells.  
Since there is no commercial source of recombinant Ebola GP1, we 
could not directly determine anti-GP1 specific IgG. Previous studies 
indicated that transient expression of the Ebola GP caused toxicity in 
mammalian cells, including cell rounding and detachment (6, 45). When 
we attempted GP1 expression in N. benthamiana, it caused severe 
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necrosis (Fig. 2), which is consistent with the effects observed in 
mammalian cells. Interestingly, when the GP1 was fused to an antibody-
forming immune complex, the toxicity of the GP1 to the leaves was 
reduced compared to the unfused GP1 (Fig. 2). Since unfolded protein 
response can contribute to cell death response (50), fusion of the GP1 to 
the IgG H-chain may allow more efficient folding in the ER, perhaps by 
recruitment of ER chaperones and the limitation of an ER stress response. 
In conclusion, this study provides evidence that the EIC can be 
produced in N. benthamiana using the geminiviral replicon system, 
accompanied by folding of GP1 into an immunogenic complex that 
contains a conformation-specific epitope. The EIC is immunogenic in 
mice, eliciting antibody levels comparable to the “gold standard” VRP-
GP1. Future work will focus on enhancing the vaccine efficacy of plant-
produced EIC by optimization of dosage and by use of adjuvants that may 
enhance cell-mediated as well as humoral immune responses. A 
challenge study will be performed to determine whether the plant-
expressed EIC can protect animals from Ebola virus infection.  
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Chapter 3 
EXPRESSION OF AN IMMUNOGENIC MOUSE EBOLA IMMUNE 
COMPLEX IN NICOTIANA BENTHAMIANA 
ABSTRACT 
The use of immune complexes can be applied to vaccine 
development since they can induce both the cell-mediated and humoral 
immune responses. In Chapter 2, we demonstrated that plant-expressed 
humanized Ebola immune complex (hEIC) is immunogenic in mice. 
However, the antibody responses induced in mice did not reach the levels 
necessary for complete protection against a lethal Ebola virus challenge. 
We hypothesized that the use of a mouse IgG backbone in the EIC, 
instead of the humanized sequence, would improve the immunogenicity of 
the EIC in mice.  In order to test this hypothesis, we produced a mouse 
Ebola immune complex (mEIC) by replacing the human antibody 
backbone in hEIC with the mouse mAb 6D8. We reconstructed the mouse 
6D8 using the heavy an light chain constant region coding sequences 
from the mouse mAb 278.02, and fusing them to plant-optimized coding 
sequences for the mouse heavy and light chain variable regions of 6D8. 
We expressed the mouse 6D8 in Nicotiana benthamiana leaves, purified 
it, and showed that it binds to irradiated Ebola virus. In the next step, we 
fused the Ebola GP1 coding sequence to the C-terminus of the heavy 
chain of the mouse mAb 6D8 to produce the mEIC. After expression and 
purification, both hEIC and mEIC were compared for their immunogenicity 
  81 
in mice. The results indicated that the levels of anti-Ebola IgG produced in 
mice immunized with mEIC is similar to that of the mice immunized with 
hEIC. Thus, even when the mAb component of the EIC matches with the 
mouse host, the EIC still does not induce sufficient antibody response for 
protection against Ebola. 
INTRODUCTION 
The success of a vaccine in inducing protective immune response 
is associated with the efficacy of vaccine uptake by antigen-presenting 
cells (APC), such as dendritic cells (DC) and macrophages. For 
vaccination to occur, APC must internalize antigens at the vaccination site 
and transport them to the lymph nodes, where the antigens are processed 
and the antigenic peptides presented on class I and class II MHC 
molecules for the activation of CD8+ and CD4+ T cells, respectively (1). A 
major factor contributing to a vaccine’s low immunogenicity can be the 
inferior capacity of APC to take up the antigen. The immunogenicity of 
vaccines can be enhanced by administering them in the form of an IC, 
which combines the antigen and antibody (Ab) specific to that antigen. 
APC such as DC and macrophages have Fcγ receptors (FcγR) that can 
bind to the Fc portion of the Ab in the IC (9, 11). This Fc/FcγR interaction 
induces the internalization of the vaccine by the APC, leading to increased 
efficiency in processing and presentation of vaccines. The immunogenicity 
of vaccines can be increased 10- to 1,000-fold when administered as the 
IC with their corresponding Abs, such as in the case of the vaccines 
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against tetanus toxoid (3, 12), hepatitis B envelope Ag (2), and Simian 
immunodeficiency virus (SIV) (13).  
In the Chapter 2, a humanized Ebola immune complex (hEIC) was 
developed by fusing the Ebola GP1 to the C-terminus of the humanized 
monoclonal antibody (mAb) 6D8. The hEIC was expressed in Nicotiana 
benthamiana leaves, extracted, and purified. After subcutaneous injection 
into mice, anti-Ebola antibodies were produced, but the antibody titer was 
not high enough for protection against a lethal Ebola virus challenge. 
Although the anti-Ebola responses were low, the mice produced high 
levels of antibodies against human IgG, which suggests that the human 
IgG backbone of hEIC was immunodominant and could interfere with 
efficient immune responses against GP1.  
Other studies showed that the administration of the IC formed with 
a xenogeneic antibody was not able to induce both humoral and cell-
mediated immune responses, whereas using syngeneic antibody in the IC 
induced both types of immune responses (6, 7). In these studies, mice 
immunized with human serum albumin (HSA) bound to rabbit anti-HSA 
IgG produced lower antibody responses to HSA as compared to the mice 
immunized with HSA bound with mouse anti-HSA IgG. 
The goal of the present study is to test whether plant-derived EIC 
containing mouse IgG, instead of human IgG, can increase the 
immunogenicity in mice. We used the mouse mAb 6D8 as the backbone in 
the IC, and used the mouse Ebola immune complex (mEIC) and hEIC 
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produced in Nicotiana benthamiana leaves to subcutaneously immunize 
mice. The immunogenicities of hEIC and mEIC were compared by 
measurement of the antibody responses against Ebola virus present in the 
serum of the immunized mice. 
MATERIALS AND METHODS 
Design of the constructs 
Plant-optimized DNA sequences encoding the variable regions for 
both the heavy and light chains of mouse mAb 6D8 were designed based 
on the sequences obtained from Mapp Biopharmaceutical, Inc. (San 
Diego, CA), using codons that are preferred in tobacco, and removing 
spurious mRNA processing signals. The plant-optimized synthetic genes 
were obtained from a commercial supplier (Integrated DNA Technologies, 
Coralville, IA). Fig. 1 shows all the constructs that were used to produce 
the mouse 6D8 mAb and the mEIC 
For pBYHGP1kdel, the constant region was amplified from the DNA 
encoding the heavy chain of the mAb 278.02 (3) using the primer 
NheImCHFor (5’-TCAGCTAGCACAACAGCCCCATCGGTCTA), which 
added  a NheI restriction site at the 5’ end and the primer 
BamHImCHBack (5’-GATGGATCCACCTCCGCCTGAACCGCCTCC), 
which added a BamHI at the 3’ end. The synthetic gene encoding the 
heavy chain variable region was digested with NcoI and NheI.   
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Fig. 1. Schematic representation of the T-DNA region of the vectors used 
in this study. 
35S/TEV5’: CaMV 35S promoter with tobacco etch virus 5’UTR; mH-kdel: 
coding sequence for mouse mAb 6D8 heavy chain with SEKDEL added to 
C-terminus, VSP3’: soybean vspB gene 3’ element, mH-GP1-kdel: coding 
sequence for mouse heavy chain-GP1 fusion, 35S/TMV5’: CaMV 35S 
promoter with tobacco mosaic virus 5’UTR, mK: coding sequence for 
mouse mAb 6D8 kappa (light) chain, rbcS3’: tobacco Rubisco small 
subunit gene 3’ element, NPT II : expression cassette encoding nptII gene 
for kanamycin resistance (yellow box), LIR (red box) : the long intergenic 
region of BeYDV genome, SIR (blue box): the short intergenic region of 
BeYDV genome, C2/C1 : BeYDV ORFs C1 and C2 which encode the  
replication initiation proteins (Rep) and RepA, LB and RB : the left and 
right borders of the T-DNA region. 
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The PCR product encoding the constant region was digested with NheI 
and BamHI. The geminiviral vector pBYH2GP1kdel (Chapter 2) was 
digested separately with BamHI/KpnI, SbfI/KpnI, and SbfI/NcoI, and the 
resulting three fragments were joined together with the NcoI/NheI and 
NheI/BamHI fragments described above in a five-piece ligation. 
For pBYK1R, the gene encoding the constant region of the light 
chain of mAb 278.02 (3) was amplified using the primer XhoImCLFor (5’-
CTGCTCGAGATCAAACGGGCTGATGCTGC), which added a XhoI 
restriction site at the 5’ end, and the primer KpnImCLBack (5’-
CTGGGTACCCTAACACTCATTCCTGTTGA), which added a KpnI site at 
the 3’ end, and the resulting product was digested with XhoI/KpnI. The 
synthetic variable region gene was obtained by digestion with NcoI and 
XhoI. The geminiviral vector pBYK3R (Chapter 2) was digested separately 
with SbfI/KpnI and SbfI/NcoI, and the resulting two fragments were joined 
together with the NcoI/XhoI and XhoI-KpnI fragments described above in a 
four-piece ligation. 
For pBYHkdel, the gene encoding the heavy chain of the mouse 
mAb 6D8 was amplified from pBYHGP1kdel using the primers H-Forward 
(5’-CCTTCGCAAGACCCTTCCTC) and H-Backward (5’-
CTCGGTACCTTAAAGCTCATCCTTCTCTGAATTCGCGCGCACGTACG
GT). The PCR product was digested with SwaI and KpnI and inserted into 
the pBYGP1kdel that had been digested with SwaI and KpnI.  
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For pBYK1R, the constant region of the light chain was amplified 
from the DNA encoding the light chain of mAb 278.02, and XhoI was 
added at the 5’ end and KpnI at the 3’ end. The variable region was 
digested with NcoI and XhoI. The constant region was digested with XhoI 
and KpnI. These two fragments were inserted into the Geminiviral vector 
pBYK3R, which was digested by NcoI, SbfI, SbfI, and KpnI by four-piece 
ligation. 
For pBYHkdel, the heavy chain of the mouse mAb 6D8 was 
amplified from pBYHGP1kdel using H-Forward (5’ ccttcgcaagacccttcctc 3’) 
and H-Backward (5’ ctcggtaccttaaagctcatccttctctgaattcgcgcgcacgtacggt 
3'). The PCR product was digested with SwaI and KpnI and inserted into 
pBYGP1kdel that had been digested with SwaI and KpnI.  
Plant inoculation and protein expression 
 N. benthamiana leaves were infiltrated with Agrobacterium by 
needle infiltration on the lower surface of leaves. The agroinfiltration 
procedure was performed as previously described in Chapter 2. For 
geminiviral constructs, the final OD600 of Agrobacterium was 0.25. Plants 
were maintained in a growth chamber. The leaves were harvested on day 
4 after infiltration. Soluble proteins were extracted by grinding the leaves 
with a Fastprep machine in 1ml of extraction buffer (phosphate-buffered 
saline (PBS), pH7.5, leupeptin, and 0.1% Tween-20) per 0.1mg of leaves. 
After centrifugation at 13,000 rpm for 5 min, the supernatant was retained 
for later analysis by ELISA and Western blot.  
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Sandwich ELISA protocol for antibody quantification 
The EIC in the plant extract was quantified by ELISA. Goat anti-
mouse IgG was diluted 1:1000 in phosphate-buffered saline (PBS, pH 7.5; 
50µl per well) and bound to 96-well polyvinylchrolide microtiter plates 
overnight at 4°C. Each plate was blocked with 5% skim mil k in PBS for 2 
hours at 37°C. After washing the wells one time with P BS containing 
0.05% Tween 20 (PBST), samples (50µl per well) diluted in 1% skim milk 
in PBST were added to the wells and incubated 1 hour at 37°C. The wells 
were washed three times with PBST and incubated with a goat anti-mouse 
kappa-horseradish peroxidase (HRP) conjugate diluted 1:4000 in 1% skim 
milk in PBST for 1 hour at 37°C. Plates were develop ed with TMB 
substrate (Pierce, Rockford, IL) for 5 min at 23°C. The  reaction was ended 
by the addition of an equal volume of 1M H2SO4, and the absorbance was 
read at 450 nm. 
SDS-PAGE and Western blot 
Plant leaf crude extracts and mouse IgG reference standard 
(Invivogen, San Diego, CA) were denatured by boiling in SDS-PAGE 
sample buffer and separated on 4–15% gradient polyacrylamide gels. 
Proteins were either visualized by Coomassie blue staining or 
electrophoretically transferred to a polyvinlidene difluoride (PVDF) 
membrane (Amersham, NJ). To detect the mouse heavy chain, the 
membrane was probed with goat anti-mouse IgG-HRP conjugate 
(SouthernBiotech, AL) diluted at 1:5000 in 1% skim milk in PBST. To 
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detect the mouse light chain, the membrane was probed with goat anti-
mouse kappa-HRP conjugate (SouthernBiotech, AL) diluted at 1:10000 in 
1% skim milk in PBST. To detect Ebola GP1, the membrane was 
incubated with human anti-6D8 (antibody against linear 6D8 epitope in 
GP1) (5) diluted 1:10000 in 1% skim milk in PBST and goat anti-human 
IgG-HRP conjugate diluted 1:10000 in 1% skim milk in PBST. The 
membranes were developed by chemiluminescence using ECL plus a 
detection reagent (Amersham, NJ).  
Protein purification 
Infiltrated tobacco leaves were homogenized by using a blender 
with extraction buffer (PBS + protease inhibitor tablet from Sigma, 
St.Louis, MO). The crude extract was filtered through Miracloth and 
centrifuged at 17,700g at 4˚C for 15 min. Ammonium sulfate was added 
into the supernatant to 35% saturation (194 g/l of the solution) and mixed 
with stirrer at 4oC for 1 hour. The solution was centrifuged at 17,700g for 
15 min, and the pellet was discarded. Ammonium sulfate was added to the 
supernatant to 60% saturation (151 g/l of the solution) and mixed with a 
stirrer at 4oC for 1 hour. The solution was centrifuged at 17,700g for 15 
min, and the pellet was dissolved with the extraction buffer. The solution 
was filtered with a 0.2 micron filter, and protein G beads (Pierce, Rockford, 
IL) was added into the filtered solution. The protein extract and the protein 
A beads were rotated at 4oC for 1 hour, and then loaded into the column 
and the resin allowed to settle. The protein A column was washed with 
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PBS, pH 7.5, and eluted with 50mM citric acid, pH 2.5. After the protein 
was eluted from the column, 1M Tris-base was added to neutralize to a 
final pH of 7.5. The purified protein was filtered through a 0.2 micron filter 
and concentrated with Amicon ultra-4 Centrifugal Filter Units-30kDa 
(Millipore, Billerica, MA). 
Ebola binding assay 
Polyvinyl chloride 96-well ELISA plates were coated with 50ml 
irradiated Ebola virus (from Dr.William Pratt, USAMRIID), diluted 1:1,000 
in PBS and incubated at 4oC overnight. Plates were blocked with 5% skim 
milk in PBST at room temperature for 2 hours. The plates were incubated 
with different concentrations of the plant-derived mouse mAb 6D8, the 
mouse mAb 6D8, and the mouse IgG (SouthernBiotech, Birmingham, AL) 
diluted in 1% skim milk in PBST for 1 hour at 37oC. HRP-conjugated goat 
anti-mouse IgG (SouthernBiotech, Birmingham, AL) was added and 
incubated for 1 hour at 37oC. The plates were developed with TMB 
substrate (KPL, Gaithersburg, MD), and the OD was read at 450 nm. 
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Mice immunization 
Female BALB/C mice were subcutaneously immunized with purified 
hEIC and mEIC from tobacco leaves. A dose of 10µg of the EIC was 
injected into each mouse. VRP-GP1 (1.6 x 108 replicons per mouse) 
injected subcutaneously was used as the positive control (provided by 
William Pratt, USAMRIID), and PBS was used as the negative control. 
The mice were immunized on day 0, 21, 42, and 63. Individual preimmune 
blood samples were collected before the first immunization, on day 0. 
Blood samples were obtained three weeks after last immunization. 
Serum antibody analysis 
The specific serum IgG response was determined by end point titer 
ELISA. Polyvinyl chloride 96-well ELISA plates were coated with 50µl of 
irradiated Ebola virus (provided by John Dye, USAMRIID) diluted 1:1000 
in PBS and incubated at 4°C overnight. Plates were bl ocked with 5% skim 
milk in PBST at 23°C for 2 hours. Subsequently, the pl ates were incubated 
with the serum diluted in 1% skim milk in PBST for 1 hour at 37°C and 
then with the HRP-conjugated goat anti-mouse IgG for 1 hour at 37°C. 
The plates were developed with TMB substrate and read OD450. 
Endpoint titer was reported as the reciprocal of the highest dilution that 
had an absorbance value ≥ 0.02 (two times the OD value for pre-immune 
serum) above the background (absorbance of the well lacking the serum). 
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RESULTS 
Transient expression, purification, and characterization of mouse 
mAb 6D8 in plants 
N. benthamiana leaves were infiltrated with different cultures of the 
A. tumefaciens strain LBA4404 bearing one of the expression constructs, 
pBYHkdel, pBYKR, or p19 (Fig. 1). After co-infiltration with all three 
constructs, the plants were harvested on day 4 after infiltration. The 
antibody was purified by using ammonium sulfate precipitation and protein 
A affinity chromatography. Fig. 2 lane 2 shows that most Rubisco protein, 
the major plant protein, was precipitated at 35% ammonium sulfate. Fig. 2 
lane 6 indicates the elution fraction from protein A chromatography, which 
has the purified antibody composed of the heavy chain and the light chain, 
was comparable to the mouse IgG standard (lane 7). Mouse mAb 6D8 
was purified to >80% purity with intact light and heavy chains (Fig. 2, lane 
6). The purified mAb was examined in a binding assay in which different 
concentrations of the plant-derived mouse mAb 6D8 were incubated with 
an irradiated Ebola virus coated on an ELISA plate. A generic mouse IgG 
was used as a negative control for the assay. The mouse mAb 6D8  (a gift 
from Dr. William Pratt, USAMRIID) was used as a positive control. Fig. 3 
shows that OD450 increased as more of the mAb 6D8 was applied in the 
reaction. In contrast, the OD450 for the generic mouse IgG remained at a 
basal level regardless of the amount of this IgG used in the reaction (Fig. 
3).   
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Fig. 2. Purification of mouse mAb 6D8 from N. benthamiana leaves. 
Infiltrated leaves were extracted, and mouse mAb 6D8 purified and 
analyzed by SDS-PAGE under reducing conditions (100mM DTT). Lane 1: 
Protein ladder; lane 2: clarified crude leaf extract; lane 3: leaf proteins 
removed by 35% ammonium sulfate precipitation; lane 4: 60% ammonium 
sulfate precipitate resuspended for protein A chromatography; lane 5: 
protein A flow-through fraction; lane 6: purified mouse mAb 6D8 in the 
protein A eluate; lane 7: mouse IgG as a reference standard 
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 Fig. 3. Plant-derived mouse mAb 6D8 shows specific binding to the Ebola 
virus. 
Plant-derived mAb 6D8, with concentrations between 0 and 2,000ng/ml, 
was incubated with irradiated Ebola virus immobilized on a 96-well ELISA 
plate. Mouse mAb 6D8 bound to the Ebola virus was detected by anti-
human IgG secondary antibody conjugated with horseradish peroxidases. 
A generic mouse IgG was used as a negative control and a mouse mAb 
6D8  (from Dr. William Pratt, USAMRIID) was used as a positive control. 
An increase in the OD450 indicates formation of the complex. 
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This result indicates that plant-produced mouse mAb 6D8 retains its 
specific affinity for the Ebola virus GP1 protein, which is similar to 
humanized mAb 6D8 produced from N. benthamiana leaves (5). 
Purification and characterization of the mouse Ebola immune 
complex from N. benthamiana leaves 
N. benthamiana leaves were infiltrated with three different cultures 
of A. tumefaciens strain LBA4404, each bearing one of three different 
constructs, pBYHGP1kdel, pBYKR, or p19 (Fig. 1). The leaves were 
harvested on days 2, 4, 6, and 8 after infiltration, and ELISA was used to 
measure the amount of the antibody. Fig. 4 shows the level of the mEIC 
expression on different days after infiltration, and the result confirms the 
highest expression level occurred on day 4 after infiltration. To purify the 
IC, we used ammonium sulfate precipitation followed by protein A affinity 
chromatography. SDS–PAGE and Coomassie blue staining of purification 
fractions showed that the combination of ammonium sulfate precipitation 
and protein A affinity chromatography effectively removed most plant host 
proteins, including the most abundant plant protein, Rubisco. Fig. 5 shows 
that the mEIC was purified from other plant proteins (lanes 6, 7, and 8). 
Western blot analysis shows that anti-mouse heavy chain, anti-mouse 
light chain, and anti-GP1 bind to the protein at the same position on a non-
reducing gel (Fig. 6a).  
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Fig. 4. Expression level of the mEIC in N. benthamiana leaves.  
The protein expression levels were measured at different times after 
agroinfiltration with the combination of pBYHGP1kdel, pBYKR, and 
pPSp19. The leaves were harvested on days 2, 4, 6, and 8 after 
infiltration. Data are means ±1SD of samples from three independent 
infiltration experiments. 
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Fig. 5. Purification of the mEIC from N. benthamiana leaves. 
Lane 1: Protein ladder; lane 2: clarified crude leaf extract; lane 3: leaf 
proteins removed by 35% ammonium sulfate precipitation; lane 4: 60% 
ammonium sulfate precipitate resuspended for protein A chromatography; 
lane 5: protein A flow-through fraction; lanes 6-9: sequential elution 
fractions from protein A chromatography. 
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B.     Anti-mouse IgG    Anti-mouse kappa chain         Anti-6D8    
 
Fig. 6. Western blotting of the mEIC.  
Crude extracts from N. benthamiana leaves agroinfiltratred with the 
combination of pBYHGP1kdel, pBYKR, and pPS19. The 100mg leaf 
samples were harvested 4 dpi and extracted with 500µl SDS sample 
buffer containing 100mM DTT, and 20µl of the extract was loaded onto the 
A.      Anti-mouse IgG    Anti-mouse kappa chain           Anti-6D8    
   1     2      3                    1     2      3                         2      3 
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gel. A. Reducing Western blot detected with anti-mouse IgG, anti-mouse 
kappa, and anti-6D8. Lane 1: mouse IgG, lane 2 wild type non-infiltrated 
plant, and lane 3: mEIC. B. Comparing reducing and nonreducing Western 
blots detected with anti-mouse IgG, anti-mouse kappa, and anti-6D8. Lane 
1: reducing sample (100mM DTT), lane2: nonreducing sample. 
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On the reducing gel, goat-anti mouse IgG detected the bands at 130, 110, 
55, and 50 kDa, similar to the hEIC (Chapter 2), whereas goat anti-mouse 
kappa and mouse anti-GP1 protein bound to the bands at 25 kDa and 130 
kDa, respectively. This result confirms the expression of mouse IgG fused 
with the Ebola GP1. 
Molecular sizing of mouse Ebola immune complex 
We assessed the diameter size of the purified EIC preparation using a 
Zetasizer Nano-ZS instrument (Malvern Instruments, UK), which 
measures the hydrodynamic diameter using dynamic light scattering. For 
these measurements, the purified mEIC, plant-made mouse mAb 6D8, 
and mouse IgG (SouthernBiotech, Birmingham, AL) were diluted in PBS, 
pH 7.5, to a concentration of 0.1mg/ml. The data show that the average 
diameter of mEIC was ~20nm, whereas plant-made mouse mAb 6D8 and 
standard mouse IgG were ~10nm (Fig. 7). The diameter of the antibody 
standard measured by Malvern Instruments (14) was also 10nm, which 
was consistent with our result. This result confirms that the mEIC is of 
similar size as the hEIC (Chapter 2). 
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Fig. 7. Hydrodynamic diameter of the mEIC or the mouse mAb 6D8 
determined by dynamic light scattering, using a Zetasizer nano-ZS 
(Malvern Instruments, UK). 
The abscissa indicates the diameter in nm, and the ordinate indicates the 
relative number of molecules at that size. Blue indicates plant-produced 
mEIC; red indicates generic mouse IgG; and green indicates plant-
produced mouse mAb 6D8. 
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Immunization study 
To compare the immunogenicities of the plant-produced mEIC and 
the hEIC, we immunized mice by subcutaneous injection, on days 0, 21, 
42, and 63 with 10µg purified hEIC or mEIC (measured as the IgG 
equivalent). We used VRP-GP1 (provided by John Dye, USAMRIID) as 
the positive control (8). Serum antibody responses were evaluated using 
ELISA with irradiated Ebola virus as the capture antigen. Fig. 8 shows that 
the mEIC induced anti-Ebola IgG at the same level as the hEIC, which is 
comparable to that obtained by immunization with VRP-GP1. This result 
indicates that the mEIC is immunogenic in mice, but the GMT of anti-
Ebola IgG in the immunized mice is approximately 200 (Fig. 8), which still 
did not reach the protection level of GMT equal to or greater than 10,000.  
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Fig. 8. Anti-Ebola IgG responses in mice immunized with the mEIC or 
hEIC. 
Four groups of seven mice each were immunized subcutaneously with 
hEIC, mEIC, VRP-GP1, or PBS. The immunizations were given on days 0, 
21, 42, and 63. The serum was collected on day 84 and assayed for anti-
Ebola IgG by ELISA, using gamma-irradiated Ebola virus as the capture 
antigen. The data are presented as GMT ±1SD for each group of mice. 
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DISCUSSION 
The results in Chapter 2 demonstrated the expression of hEIC in N. 
benthamiana leaves and its immunogenicity. However, the hEIC was not 
sufficiently immunogenic in mice. In this chapter, we tested whether the 
immunogenicity of the IC in mice would be improved if a mouse, rather 
than human, antibody backbone was used in the IC. The mEIC was 
expressed and purified in N. benthamiana leaves. Mouse  mAb 6D8 was 
constructed and used for fusion with the Ebola GP1. The plant-produced 
mouse mAb 6D8 bound to irradiated Ebola virus (Fig. 3), which indicates 
the potential for EIC formation. The measured size of the mEIC (~20nm) is 
larger than the antibody alone (10nm), which suggests that a complex was 
formed.  
The level of anti-Ebola antibody in mice immunized with the mEIC 
was not significantly different from the groups immunized with the hEIC or 
VRP-GP1. Although the antibody backbone used in the mEIC is syngeneic 
with the mouse host, the mEIC still does not induce a high antibody level, 
as was observed with hEIC. Thus, the hypothesis that use of a syngeneic 
antibody in the IC would enhance the immune response is rejected.  
 Antigen-antibody IC can induce the immune response because the 
IC can bind to the Fc receptor on APC, thus enhancing the presentation of 
antigenic epitope to T cells. One study (12) found that anti-Fc receptor 
antibodies blocked the clearance of the IC from the blood. Thus, the Fc 
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region on the antibody is implicated as a factor in the immunogenicity of 
the IC. 
 For the EIC, because the structure of the Ebola GP1 is unknown, it 
is also unknown whether the structure of the Ebola GP1 hinders the Fc 
region on the mAb 6D8. If the structure of the Ebola GP1 affects the Fc 
region, this might explain why the EIC cannot induce high antibody titers. 
In this study, (G4S)2 was used as the linker between the mouse 6D8 heavy 
chain and the GP1; (G4S)3 was used as the linker in the hEIC (Chapter 2). 
Both are short and flexible linkers. For future work, different linkers could 
be tested for their enhancement of the EIC's immunogenicity. Further 
experiments should include using the truncated version of the GP1 to fuse 
to the heavy chain of  the mAb 6D8. If the structure of the full-length GP1 
protein hinders the Fc region on the mAb 6D8, using a smaller part of the 
Ebola GP1 protein containing the 6D8 epitope might increase the 
immunogenicity of the EIC. 
 In addition, another experiment to avoid the putative effect of the 
Ebola GP1 structure on the Fc region of the antibody involves mixing the 
Ebola GP1 protein with the mAb 6D8 in vitro before immunization. When 
the Ebola GP1 is mixed with the mAb 6D8, the variable region of the  mAb 
6D8 will bind to the 6D8 epitope in the Ebola GP1. The structure of the 
Ebola GP1 protein will then not affect the Fc region on the mAb 6D8. One 
potential problem with this experiment is that the Ebola GP1 is highly toxic 
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to host cells, causing cell rounding and detachment (13, 14). Thus, 
production of the Ebola GP1 protein is difficult.  
Another possibility that might reduce the immunogenicity of the EIC 
is plant glycosylation. In this study, we used the wild type N. benthamiana 
plants as the expression host. The glycosylation pattern of protein 
produced in plants is different from mammalian cells (4, 10). For example, 
plants only produce bi-antennary N-glycans, whereas the N-glycans in 
mammals can be more branched. In this work, we added the C-terminal 
hexapeptide SEKDEL, which is an ER retention signal, to GP1. This 
causes the EIC to be retained in the ER and to have a high mannose N-
glycan pattern. To test whether the plant glycosylation affects the 
immunogenicity of the EIC, the EIC could be produced in a genetically 
modified plant, so as to have a glycosylation pattern similar to mammalian 
cells. The down-regulation of the endogenous β-1,2-xylosyltransferase 
(XylT) and α-1,3-fucosyltransferase (FucT) genes in N. benthamiana can 
produce plants with significantly reduced xylosylated and/or core α-1,3-
fucosylated glycan structures, which produces a more human-like N-
glycan structure (15). To test whether plant glycosylation affects the 
immunogenicity of the EIC, the IC can be expressed in such a modified 
plant with human-like N-glycan and constructed without the SEKDEL 
sequence. Both XyIT and FucT enzymes are in the Golgi apparatus. As 
we have shown here, if SEKDEL is added at the C-terminus of the Ebola 
GP1 gene, the protein will be retained in the ER, and the glycosylation 
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pattern will be a high mannose N-glycan, which is different from 
mammalian glycan. If the EIC is produced in a genetically modified plant 
producing human-like N-glycans, it could be used to immunize the mice. If 
plant glycosylation is a factor that affects the binding to the Fc receptor 
and the immunogenicity of the EIC, the EIC produced from this modified 
plant, when used to immunize mice, should result in increased immune 
response to Ebola virus in the mice. 
In summary, the EIC produced in N. benthamiana is immunogenic 
in mice, because it can induce an antibody response against Ebola virus. 
Although the level of the antibody against Ebola virus still does not reach 
the titer required for the protection against a lethal Ebola challenge, there 
are additional studies that can be conducted with the objective of 
increasing the immunogenicity of EIC. Moreover, adjuvants can be 
administered along with the EIC to enhance its immunogenicity. Different 
adjuvants should be studied to test which one works best with the EIC. 
Ensuring protection against Ebola lethal challenge is crucial for any new 
vaccine, necessitating further research to improve immunogenicity of 
recombinant antigens. 
 
  107 
REFERENCES 
1. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and 
the control of immunity. Nature 392:245-52. 
 
2. Celis, E., and T. W. Chang. 1984. Antibodies to hepatitis B surface 
antigen potentiate the response of human T lymphocyte clones to 
the same antigen. Science 224:297-9. 
 
3. Chargelegue, D., P. M. Drake, P. Obregon, A. Prada, N. 
Fairweather, and J. K. Ma. 2005. Highly immunogenic and 
protective recombinant vaccine candidate expressed in transgenic 
plants. Infect Immun 73:5915-22. 
 
4. Gomord, V., A. C. Fitchette, L. Menu-Bouaouiche, C. Saint-
Jore-Dupas, C. Plasson, D. Michaud, and L. Faye. Plant-specific 
glycosylation patterns in the context of therapeutic protein 
production. Plant Biotechnol J 8:564-87. 
 
5. Huang, Z., W. Phoolcharoen, H. Lai, K. Piensook, G. Cardineau, 
L. Zeitlin, K. J. Whaley, C. J. Arntzen, H. S. Mason, and Q. 
Chen. 2010. High-level rapid production of full-size monoclonal 
antibodies in plants by a single-vector DNA replicon system. 
Biotechnol Bioeng 106:9-17. 
 
6. Marusic-Galesic, S., M. Marusic, and B. Pokric. 1992. Cellular 
immune response to the antigen administered as an immune 
complex in vivo. Immunology 75:325-9. 
 
7. Marusic, M., S. Marusic-Galesic, and B. Pokric. 1992. Humoral 
immune response to the antigen administered as an immune 
complex. Immunol Invest 21:623-8. 
 
8. Pushko, P., M. Bray, G. V. Ludwig, M. Parker, A. Schmaljohn, 
A. Sanchez, P. B. Jahrling, and J. F. Smith. 2000. Recombinant 
RNA replicons derived from attenuated Venezuelan equine 
encephalitis virus protect guinea pigs and mice from Ebola 
hemorrhagic fever virus. Vaccine 19:142-53. 
 
9. Regnault, A., D. Lankar, V. Lacabanne, A. Rodriguez, C. Thery, 
M. Rescigno, T. Saito, S. Verbeek, C. Bonnerot, P. Ricciardi-
Castagnoli, and S. Amigorena. 1999. Fcgamma receptor-
mediated induction of dendritic cell maturation and major 
histocompatibility complex class I-restricted antigen presentation 
after immune complex internalization. J Exp Med 189:371-80. 
 
  108 
10. Schahs, M., R. Strasser, J. Stadlmann, R. Kunert, T. 
Rademacher, and H. Steinkellner. 2007. Production of a 
monoclonal antibody in plants with a humanized N-glycosylation 
pattern. Plant Biotechnol J 5:657-63. 
 
11. Schuurhuis, D. H., A. Ioan-Facsinay, B. Nagelkerken, J. J. van 
Schip, C. Sedlik, C. J. Melief, J. S. Verbeek, and F. Ossendorp. 
2002. Antigen-antibody immune complexes empower dendritic cells 
to efficiently prime specific CD8+ CTL responses in vivo. J Immunol 
168:2240-6. 
 
12. Stoner, R. D., and G. Terres. 1963. Enhanced Antitoxin 
Responses In Irradiated Mice Elicited By Complexes Of Tetanus 
Toxoid And Specific Antibody. J Immunol 91:761-70. 
 
13. Villinger, F., A. E. Mayne, P. Bostik, K. Mori, P. E. Jensen, R. 
Ahmed, and A. A. Ansari. 2003. Evidence for antibody-mediated 
enhancement of simian immunodeficiency virus (SIV) Gag antigen 
processing and cross presentation in SIV-infected rhesus 
macaques. J Virol 77:10-24. 
 
14. http://www.malvern.com/common/downloads/campaign/MRK880-
01.pdf 
  109 
Chapter 4 
PLANT-PRODUCED EBOLA IMMUNE COMPLEX CO-DELIVERED 
WITH TLR3 AGONIST PROTECTS MICE FROM A LETHAL EBOLA 
CHALLENGE 
ABSTRACT 
Ebola hemorrhagic fever (EHF) is a fatal disease in humans caused 
by the Ebola virus. Currently, there are no specific and effective 
treatments or vaccines for EHF. Hence, there is an urgent need for a safe 
and effective vaccine. The goal of this study was to evaluate the 
immunogenicity and efficacy of a novel plant-produced Ebola vaccine 
candidate, the Ebola immune complex (EIC), because it was shown to be 
immunogenic in mice. As noted in the studies presented in Chapters 2 and 
3, the EIC delivered subcutaneously in mice was not highly immunogenic. 
Therefore, the present study was designed to evaluate two Toll-like 
receptor (TLR) agonists as adjuvants co-delivered with the EIC. Mice were 
immunized subcutaneously with the hEIC (Chapter 2) alone or the hEIC 
co-administered with a TLR3 agonist [polyinosine-polycytidylic acid (PIC)] 
and/or a TLR7/8 agonist (CL097). A Venezuelan Equine Encephalitis 
replicon particle expressing the Ebola GP1 (VRP-GP1) was used as a 
positive control for immunization, and PBS was used as a negative 
control. The hEIC co-delivered with PIC elicited a strong antibody 
response, which was comparable to that elicited by VRP-GP1. PIC and 
CL097 delivered together with the hEIC did not result in a synergistic 
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effect with regard to antibody production. To determine whether the hEIC 
co-administered with an adjuvant could protect the mice against a lethal 
Ebola challenge, the hEIC was delivered with either PIC or alum followed 
by a live Ebola virus challenge. Although immunization with the  hEIC 
alone could not protect the mice, the hEIC co-delivered with PIC protected 
80% of the mice from a lethal challenge, similar to immunization with VRP-
GP1 (p=0.7630). In contrast, the hEIC co-delivered with alum could not 
significantly (p=0.5772) protect mice from a lethal Ebola challenge relative 
to PBS mock-immunized mice. The levels of total anti-Ebola IgG and the 
neutralizing antibody specific to Ebola virus were directly correlated with 
the level of protection afforded by the vaccine candidate. Moreover, the 
titers of each IgG subtype demonstrated that the hEIC alone and the hEIC 
co-delivered with alum induced a T-helper type 2 (Th2) dominant 
response, whereas the hEIC co-administered with PIC induced a mixed 
Th1/Th2 response. These results suggest that a mixed Th1/Th2 response 
facilitates the protection afforded by this vaccine. The protective efficacy of 
the hEIC co-administered with PIC against a lethal Ebola virus challenge 
in mice affirms the need for further study in non-human primates and 
humans for the development of an effective Ebola vaccine.  
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INTRODUCTION 
Ebola hemorrhagic fever is a severe and often-fatal disease that 
can occur in human and nonhuman primates, such as chimpanzees, 
monkeys, and gorillas (45). Ebola virus can cause lethal hemorrhagic 
disease in humans, with a very high mortality rate, up to 90%, and with 
clinical symptoms arising quickly after an incubation period from 2 to 21 
days (33). The typical presentation is characterized by flu-like symptoms 
including high fever, chills, malaise, and myalgia. The ensuing symptoms 
indicate multisystem involvement, including systemic, gastrointestinal, 
respiratory, vascular, and neurologic manifestations. Abnormalities in 
blood coagulation appear as petechiae, ecchymoses, mucosal 
hemorrhages, and uncontrolled bleeding in venipuncture sites. Severe 
Ebola infection usually progresses to shock, convulsions, and diffuse 
coagulopathy. Death or recovery typically happens 6–9 days after the 
onset of clinical symptoms (24, 43). Not only do the dramatic clinical 
symptoms and high fatality rate of the Ebola virus infection make it 
extremely dangerous, but additionally, all Ebola virus strains have 
displayed the ability to be spread through aerosols under research 
conditions (13, 29, 31). Therefore, Ebola virus is a potential deadly 
bioweapon that could be used by terrorists, especially given that  
approximately 30 years after the first epidemic, there is yet no approved 
vaccine or therapeutic for the Ebola virus. 
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The primary difficulty for patients in recovering from an Ebola virus 
infection is the failure of their immune systems to react to this rapidly 
progressing disease. The patients who die from Ebola hemorrhagic fever 
are unable to develop an adequate immune response in the face of 
extreme viremia and multi-organ infection. Previous studies have shown 
that survivors from an Ebola infection must develop early and increasing 
levels of IgG against the Ebola virus followed by viral antigen clearance 
and cytotoxic T cell activation. In fatal cases, Ebola-specific IgG and T 
cell-related mRNA were not detected (3). These data imply that both 
humoral and cell-mediated immune responses are important for recovery 
from an Ebola infection. Thus, the key for Ebola vaccine development is to 
find a candidate that activates both antibody and cytotoxic T cell 
responses against the Ebola virus. 
Several different types of Ebola vaccine have been developed 
previously, including the DNA vaccine (16, 38, 61), the Ebola virus-like 
particle (VLP) (39, 58, 66, 71), the vesicular stomatitis virus-based vaccine 
(19, 20), the adenovirus vector (34, 63, 64, 70), and the Venezuelian 
equine encephalitis virus (VEE) replicon particle (VRP) (44, 47). However, 
there is no approved vaccine for human use at present. In Chapter 2, we 
showed production of the humanized Ebola immune complex (hEIC) in 
Nicotiana benthamiana as a vaccine candidate, by fusing the Ebola GP1 
at the C-terminus of the heavy chain of the humanized monoclonal 
antibody (mAb) 6D8 (Fig. 1).  
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Fig. 1. Diagram illustrating the structure and assembly of the hEIC. 
The hEIC was designed and expressed by fusing Ebola GP1 to the C-
terminus of the humanized heavy chain of mAb 6D8  (A, left). The 
recombinant IgG can bind to the Ebola GP1 and form an immune complex 
(A, center). Female BALB/C mice were immunized with hEIC 
subcutaneously, with or without candidate adjuvants, following the 
designed immunization schedule (B). Mice were immunized on days 0, 21, 
42, and 63 for the 3-dose groups or on days 21, 42, and 63 for the 4-dose 
groups. Blood was collected 2 weeks after each immunization (days 14, 
35, and 56) and 3 weeks after the last immunization (day 84). For the 
challenge study, mice were lethally challenged with the  Ebola virus 3 
three weeks after the last immunization (day 84). 
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After the fusion protein was co-expressed with the light chain of mAb 6D8, 
assembly of IgG occurred that allowed formation of the hEIC. We 
subcutaneously immunized mice with purified hEIC and showed 
immunogenicity, but the mice did not develop sufficient immune responses 
to protect them against a lethal Ebola virus challenge.  
In this study, we used different TLR agonists and alum as adjuvants 
with hEIC in order to determine which one produces the best protection of 
mice from an Ebola lethal challenge. 
TLR are a type of pattern recognition receptors of the innate 
immune system that recognize different molecules broadly shared by 
pathogen (35). For example, TLR 7/8 recognize single-stranded RNA 
whereas TLR3 recognizes double-stranded RNA from the virus and can 
induces the activation of NF-kB to increase production of type I interferons 
which signal other cells to increase their antiviral defenses (5). TLR 
ligands, which mimic pathogen-associated molecular patterns and activate 
immune cells via TLR, can be used in humans as vaccine adjuvants (11, 
18, 28, 30, 67, 72, 73). Poly(I:C) (PIC) and CL097, which are TLR3 and 
TLR7/8 agonists, respectively, were chosen to use in this study because 
both can mimic viral RNA, and the Ebola virus has a RNA genome. 
Moreover, we also studied alum as another adjuvant, because it is the 
only classical adjuvant which is approved by the FDA for use in humans 
(7, 51).  
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 In this study, we demonstrate that the hEIC delivered with PIC 
induced a high IgG antibody response against the Ebola virus and  
protected the immunized mice from an Ebola lethal challenge. The hEIC 
delivered alone induced a Th2 dominant response against the Ebola virus, 
and provided no protection in a lethal Ebola virus challenge. When PIC 
was co-administered with the hEIC, the mice produced a mixed Th1/Th2 
response, which correlated with protection against the lethal Ebola virus 
challenge. These results support the candicacy of plant-expressed hEIC 
as a vaccine for Ebola virus in humans.  
MATERIALS AND METHODS 
Ebola immune complex preparation 
The binary vectors (see Chapter 2, page 43, and Chapter 3, page 
83 were introduced into Agrobacterium tumefaciens LBA4404 by 
electroporation. The final OD600 of Agrobacterium infiltrated into the leaves 
was 0.25. For the hEIC, N. benthamiana leaves were co-infiltrated with 
pBYRH2GP1kdelK3 and pPS19. For the mouse Ebola immune complex 
(mEIC), the leaves were co-infiltrated with pBYHGP1kdel, pBYKR, and 
pPS19. The infiltrated leaves were harvested on day 4 after infiltration. 
The leaves were extracted, and the proteins were purified by protein G or 
protein A affinity chromatography for the hEIC or the mEIC, respectively, 
followed by ammonium sulfate precipitation (described in Chapter 2 and 
Chapter 3). 
 
  116 
Preparation of N-linked glycans and MALDI-TOF/TOF MS analysis 
The preparation and purification of glycans derived from total 
endogenous leaf proteins were performed as described by Strasser et al. 
(56). Mass spectrometric analysis of endogenous glycans was carried out 
with a Bruker Ultraflex MALDI-TOF/TOF mass spectrometer (Bruker 
Daltonics, Bremen, Germany) in reflector mode at positive ionization. The 
matrix was 2,5-dihydroxybenzoic acid (DHB) [2% (w/v) DHB in 50% (v/v) 
acetonitrile in H2O]. 
Immunization  
To test the antibody response of the mice immunized with the EIC 
co-administered with PIC and/or CL097, seven female BALB/C mice in 
each group were immunized subcutaneously with 10µg EIC alone, 10µg 
EIC co-administered with PIC, CL097, or the combination of PIC and 
CL097. The immunizations were performed on days 0, 21, 42, and 63. 
The pre-immune blood samples were obtained on day 0 before the first 
immunization, and the sera wereanalyzed for anti-Ebola IgG by ELISA on 
day 14, 35, 56, and 84 (Fig. 1B). For the challenge study, 15 female 
BALB/C mice in each group were subcutaneously immunized with 10µg 
EIC, 10µg EIC co-delivered with alum (Sigma, St. Louis, MO), PIC 
(Invivogen, San Diego, CA), or with the combination of alum and PIC on 
days 0, 21, 42, and 63. Two groups were subcutaneously immunized with 
10µg EIC co-administered with PIC or 25µg EIC co-delivered with PIC and 
alum were injected on days 0, 21, and 42. Groups of mice were 
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immunized with four doses of VRP-GP1 (47), or PBS as positive and 
controls, respectively. Ten mice in each group were shipped to USAMRIID 
on day 70 and infected with the Ebola virus on day 84. Five mice from 
each group were bled on day 84 by cardiac puncture and analyzed for IgG 
specific for Ebola virus by ELISA. 
Ebola virus challenge  
Mouse-adapted Ebola virus was obtained from Dr. Mike Bray (6). 
Research was conducted in compliance with the Animal Welfare Act and 
other federal statutes and regulations related to animals and experiments 
involving animals and adhered to principles stated in the Guide for the 
Care and Use of Laboratory Animals (National Research Council, 1996). 
The facility where this research was conducted is fully accredited by the 
Association for the Assessment and Accreditation of Laboratory Animal 
Care International. For infection, mice were inoculated intraperitoneally 
(i.p.) with 1000 PFU (30,000 LD50) of mouse-adapted Ebola virus in a 
Biosafety Level 4 (BSL-4) laboratory. The survival was recorded for 30 
days. The average weight of all surviving mice was measured for 14 days. 
Anti-Ebola antibody analysis by ELISA  
Anti-Ebola antibody was measured by ELISA as described in 
Chapters 2 and 3. Briefly, polyvinyl chloride 96-well ELISA plates were 
coated with 50µl of irradiated Ebola virus diluted 1:1000 in PBS and 
incubated at 4oC overnight. Plates were blocked with 5% skim milk in 
PBST at 23oC for 2 hours. Subsequently, the plates were incubated with 
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the serum diluted in 1% skim milk in PBST for 1 hour at 37oC and then 
with HRP-conjugated goat anti-mouse IgG for 1 hour at 37oC. The plates 
were developed with TMB substrate and read OD450. For IgG1, IgG2a, 
IgG2b, and IgG3 antibody titers, HRP-conjugated goat anti-mouse IgG1, 
IgG2a, IgG2b, or IgG3 were used to detect, respectively. 
Neutralizing antibody measurement  
Four ten-fold serial dilutions of serum were mixed with 100 plaque-
forming units of Ebola Zaire at 37°C for 1 hour and used to infect Vero cell 
monolayers. Cells were overlaid with agarose, and a second overlay 
containing 5% neutral red was added 7 days later. Plaques were counted 
the next day. Neutralization titers were determined to be the last dilution of 
serum that reduced the number of plaques by 80% compared with control 
wells. 
Ebola virus competition binding assay 
Polyvinyl chloride 96-well ELISA plates were coated with 50µl of 
irradiated Ebola virus diluted 1:1000 in PBS and incubated at 4˚C 
overnight. Plates were blocked with 5% skim milk in PBST at 23˚C for 2 
hours. Subsequently, the plates were incubated with the mouse serum 
alone diluted 1:10, 1:100, or 1:1,000 in 1% skim milk in PBST or mouse 
serum combined with 100µg/ml or 10µg/ml plant-produced humanized 
mAb 6D8 diluted 1:10 in 1% skim milk in PBST for 1 hour at 37˚C and 
then with HRP-conjugated goat anti-mouse IgG for 1 hour at 37˚C. The 
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plates were developed with TMB substrate, and the OD450 was 
determined.  
Statistical analysis  
The survival data and IgG titers were analyzed by the log rank test 
and the Kruskal-Wallis Test using GraphPad Prism 5 (GraphPad 
Software), respectively. Statistical significance was determined at the level 
of P < 0.5. 
RESULTS 
The mAb 6D8 glycosylation patterns are similar in wild type and 
humanized N-glycan N. benthamiana. 
 To examine the N-glycan compositions of the mAb 6D8 produced in 
the wild type and the humanized N-glycan N. benthamiana, purified 
humanized mAb 6D8 and mouse mAb 6D8 from both types of plants were 
subjected to matrix-assisted laser desorption ionization-time of flight/time 
of flight mass spectrometry (MALDI-TOF/TOF MS) analysis. The results 
showed no differences in the N-glycan compositions of antibodies 
produced from the wild type or the humanized N-glycan N. benthamiana. 
Fig. 2 and Fig. 3 show that both the human IgG and the mouse IgG from  
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Fig. 2. MALDI-TOF/TOF MS of human mAb 6D8 extracted and purified 
from N. benthamiana leaves. 
N-glycan compositions of human IgG produced in wild type (upper panel) 
and the humanized N-glycan N. benthamiana (lower panel) are similar.  
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Fig. 3. MALDI-TOF/TOF MS of mouse mAb 6D8 extracted and purified 
from N. benthamiana leaves. 
N-Glycan compositions of the mouse IgG produced in the wild type and 
the humanized N-glycan N. benthamiana are similar.  
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either the wild type or the humanized N-glycan plants contained N-glycan 
species that carried high mannose structures with eight mannose units 
(mass 2891) and nine mannose units (mass 3053). 
PIC enhances anti-Ebola IgG production when it is co-administered 
with EIC whereas CL097 does not.  
Both the hEIC and the mEIC were expressed in N. benthamiana 
leaves using a geminiviral replicon system (25, 26). After expression and 
purification, the hEIC and mEIC were used to immunize mice. We 
subcutaneously immunized mice with four doses of hEIC with PIC, CL097, 
or the combination of PIC and CL097. Anti-Ebola IgG in the sera (Fig. 4) 
significantly increased in mice immunized with hEIC compared to the PBS 
control group (p=0.0248). When hEIC with CL097 was used to immunize 
the mice, anti-Ebola IgG also significantly increased, as compared to the 
PBS control group, but it was not significantly different from that of the 
mice immunized with hEIC alone (p=0.6198). However, using hEIC with 
PIC to immunize the mice significantly increased the anti-Ebola response 
compared to immunization with hEIC alone (p=0.0016). Immunization 
using the combination of PIC and CL097 with hEIC produced antibody 
titers in mice that were not significantly different from those of mice that 
were immunized with hEIC and PIC alone (p=0.5030), but were 
significantly higher than those in mice immunized with CL097 and hEIC 
(p=0.0019).   
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Fig. 4. Co-delivery of PIC with hEIC in mice induced the highest anti-Ebola 
IgG antibody response relative to other TLR agonist combinations and the 
PBS negative control.  
Groups were subcutaneously immunized with 10µg hEIC alone, hEIC with 
CL097, hEIC with PIC, or hEIC with CL097+PIC on days 0, 21, 42, and 
63. VRP-GP1 was used as the positive control. Anti-Ebola IgG titers were 
measured by ELISA on days 0, 14, 35, 56, and 84. GMT was defined as 
the highest serum dilution giving a positive reaction. The GMT for the PBS 
negative control group and preimmune (day 0) serum in all groups were ≤ 
1 (not shown). The error bars indicate the standard deviation (SD). The 
data presented are representative of three independent studies. 
Statistically significant differences (p<0.05) in the levels of IgG anti-Ebola 
were determined by the Kruskal-Wallis test. Comparisons were made 
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between immunization groups relative to PBS control. * P < 0.05, ** p ≤ 
0.01, *** p ≤ 0.001. 
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Immunization with the EIC and PIC protected mice from a lethal 
Ebola virus challenge. 
To assess the efficacy of the EIC against a lethal Ebola virus 
challenge, vaccinated mice were given 30,000 LD50 of Ebola virus i.p. 3 
weeks after the last immunization. All studies with live Ebola virus were 
performed under BSL4 conditions in accordance with guidelines of the 
National Institutes of Health and the Centers for Disease Control. Four 
doses of hEIC co-delivered with PIC alone or co-administered with PIC 
and alum both induced 80% protection against the lethal virus challenge, 
as measured by survival (Fig. 5), which is not statistically different from the 
90% protection afforded in the group that received four doses of VRP-GP1 
(p= 0.7630 and 0.7835, respectively). The immunizations with four doses 
of hEIC alone or hEIC co-administered with alum did not protect the mice; 
all 10 mice died, which was not statistically different from the PBS 
negative control group (p= 0.5577 and 0.5772, respectively). When three 
doses of PIC and alum were co-administered with hEIC, the survival rate 
was 20%, which was not significantly different from PBS (p= 0.0860). The 
group that was immunized with three doses of 25µg of hEIC (compared to 
10µg in other groups) with PIC and alum was the only group to show 50% 
protection, which was statistically different from PBS group (p=0.0058). 
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Fig. 5. The hEIC co-delivered with PIC significantly protected mice from 
the Ebola lethal challenge.  
Immunization with 3 or 4 doses of 10µg of the hEIC, or 3 doses of 25µg  of 
the hEIC, with or without candidate adjuvants was performed in mice 
(n=10 per group). Mice were immunized on days 0, 21, 42, and 63 for the 
3 doses group or days 0, 21, 42, and 63 for the 4 dose groups and 
challenged i.p. with 1000 PFU (30,000 LD50) of the mouse-adapted Ebola 
virus on day 84. The survival was reported for 30 days. Statistically 
significant differences (p<0.05) in survival were determined by the log rank 
test, and comparisons were made between immunization groups relative 
to PBS control as indicated (*). 
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Table 1 displays the p values calculated from the log rank test to 
compare the survival rates between two paired immunization groups. The 
protection afforded by 10µg of the hEIC co-administered with PIC in four 
doses, 10µg of the hEIC co-delivered with PIC and alum in four doses, 
and 25µg of the hEIC co-administered with PIC and alum in three doses 
were not statistically different from the VRP-GP1 positive control group. 
Weight losses of the mice after they were challenged with Ebola virus are 
shown in Fig. 6. The mice immunized with VRP-GP1 experienced less 
weight loss than the mice in other groups. Mice in the groups immunized 
with hEIC + PIC or hEIC + PIC + alum showed disease symptoms and lost 
weight on day 4; the surviving mice recovered from the disease and 
gained more weight on day 7. Immunization with hEIC alone, thus delayed 
weight loss, which delayed the course of the disease, as compared to the 
PBS negative control group, in which the immunized mice showed weight 
loss on day 1 after the challenge.  
The survival and weight loss of the mice immunized with the mEIC, 
with or without different adjuvants, are presented in Fig. 7 and Fig. 8, 
respectively. Fig. 7 shows that 70% of the mice immunized with the mEIC 
+ PIC + alum were protected from Ebola infection, which is not statistically 
different from the mice immunized with VRP-GP1 (p=0.5364). The levels 
of anti-Ebola total IgG in mice immunized with the hEIC and the mEIC are 
shown in Fig. 9 and Fig. 10, respectively. 
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VRP-GP1 
4doses 
hEIC 4 
doses 
hEIC+Alu
m 4doses 
hEIC+PIC 
4doses 
hEIC+Alu
m+PIC 
3doses 
hEIC+Alu
m+PIC 
4doses 
25ughEIC
+Alum+PI
C 4doses 
PBS 
4doses 
VRP-GP1 
4doses 
 
NA 0.0002*** 0.0003*** 0.763 0.0101* 0.7835 0.1488 0.0005*** 
hEIC 
4doses 
 
0.0002*** NA 0.2612 <0.0001**
* 
0.0309* <0.0001**
* 
0.0018** 0.5577 
hEIC+alu
m 4doses 0.0003*** 0.2612 NA 0.0001*** 0.1459 
<0.0001**
* 
0.006** 0.5772 
hEIC+PIC             
4 doses 0.763 
<0.0001**
* 
0.0001*** NA 0.0065** 0.948 506 0.0002*** 
hEIC+alu
m+PIC 
3doses 
0.0101* 0.0309* 0.1459 0.0065** NA 0.0045** 0.1451 0.086 
hEIC+alu
m+ 
PIC 4 
doses 
0.7835 <0.0001**
* 
<0.0001**
* 
0.948 0.0045** NA 0.1405 <0.0001**
* 
hEIC25ug
+alum+PI
C 3doses 
0.1488 0.0018** 0.006** 0.1506 0.1451 0.1405 NA 0.0058** 
PBS 4 
doses 
 
0.0005*** 0.5577 0.5772 0.0002*** 0.086 <0.0001**
* 
0.0058** NA 
 
Table1. The P value calculated from the log rank test determines the 
statistical difference in survival from the Ebola virus challenge between 
two immunization groups when p value < 0.05.  
* P<0.01-0.05, ** P <0.009-0.001, *** P<0.0009-0.0001, NA, not applicable 
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Fig. 6. Body weight change after Ebola virus infection in mice immunized 
with the hEIC alone or the hEIC with different adjuvants. 
Immunization with 3 or 4 doses of the hEIC alone or the hEIC with 
candidate adjuvants was performed in mice (n=10 per group). The group 
immunized with hEIC 25µg + alum + PIC received 3 doses. All other hEIC-
immunized mice received 10µg hEIC per dose. Mice were immunized on 
days 0, 21, 42, and 63 for the groups receiving 3 doses, or days 0, 21, 42, 
and 63 for the groups receiving 4 doses, and challenged i.p. with 1000 
PFU (30,000 LD50) of the mouse-adapted Ebola virus on day 84. The 
body weight change was measured for 14 days. 
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Fig. 7. The mEIC co-delivered with PIC significantly protected mice from 
lethal Ebola virus challenge.  
Immunization with 4 doses of the mEIC alone or with the mEIC with 
candidate adjuvants was performed in mice (n=10 per group). Mice were 
immunized on days 0, 21, 42, and 63 and challenged i.p. with 1000 PFU 
(30,000 LD50) of the mouse-adapted Ebola virus on day 84. The survival 
was reported for 30 days. Statistically significant differences (p<0.05) in 
survival were determined by the log rank test, and comparisons were 
made between immunization groups relative to a PBS control as indicated 
(*).  
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Fig. 8. Body weight change after Ebola virus infection in mice immunized 
with the mEIC alone or the mEIC with different adjuvants.  
Immunization with 4 doses of the mEIC with or without different adjuvants 
was performed in mice (n=10 per group). Mice were immunized on days 0, 
21, 42, and 63 and challenged i.p. with 1000 PFU (30,000 LD50) of 
mouse-adapted Ebola virus on day 84. The body weight change was 
measured for 14 days. 
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Fig. 9. Anti-Ebola IgG levels in mice immunized with the hEIC alone or 
with different adjuvants. 
Mice (n=5 per group) immunized with the hEIC, as described for the 
challenge study (Figs. 5 and 6), were bled 2 weeks after each 
immunization and 3 weeks after the last immunization (on days 14, 35, 56, 
and 84 for the groups receiving 3 doses, or days 0, 14, 35, 56, and 84 for 
the groups receiving 4 doses). Individual serum samples for the mice in 
each immunization group were analyzed for anti-Ebola IgG by ELISA. The 
GMT for preimmune (day 0) serum in all groups were ≤ 1 (data not 
shown). The error bars indicate the SD. Statistically significant differences 
(p<0.05) in the levels of anti-Ebola IgG were determined by the Kruskal-
**
***
**
**
**
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Wallis test. Comparisons were made between immunization groups 
relative to PBS control. * P < 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
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Fig. 10. Anti-Ebola IgG levels in mice immunized with the mEIC alone or 
with different adjuvants. Mice (n=5 per group) immunized as described for 
the challenge study (Figs. 7 and 8) were bled 2 weeks after each 
immunization and 3 weeks after the last immunization (on days 0, 14, 35, 
56, and 84). Individual sera were analyzed for total IgG specific to the 
Ebola virus by ELISA. The GMT for preimmune (day 0) sera in all groups 
were ≤ 1 (data not shown). The error bars indicate the SD. Statistically 
significant differences (p<0.05) in the level of IgG anti-Ebola were 
determined by the Kruskal-Wallis test. Comparisons were made between 
the immunization groups relative to PBS control. * P < 0.05, ** p ≤ 0.01, *** 
p ≤ 0.001. 
*
***
****
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The levels of neutralizing antibody specific to Ebola virus in mice 
immunized with the hEIC and the mEIC are presented in Fig. 11 and Fig. 
12, respectively. For mice immunized with the hEIC, the levels of anti-
Ebola IgG were highest in the groups of mice immunized with 4 doses of 
the hEIC + PIC (red) and with the hEIC + PIC + alum (blue) (Fig. 9); the 
levels of virus-neutralizing antibody were highest in mice immunized with 
the hEIC + PIC + alum (blue) and hEIC + PIC (red), respectively (Fig. 11). 
The anti-Ebola IgG and virus-neutralizing antibody titers in these two 
groups were correlated with the level of protection against Ebola virus 
challenge, which was comparable to that in the mice immunized with VRP-
GP1 (Fig. 5). Immunization with the mEIC + PIC + alum protected 70% of 
the mice from lethal Ebola virus challenge, which is not significantly 
different from the level of protection in the mice immunized with VRP-GP1 
(p=0.5364) (Fig.7). The levels of anti-Ebola IgG in the mice immunized 
with the mEIC + PIC + alum was highest among the groups (Fig.10), and 
was directly correlated to the protection level (Fig.7). However, the levels 
of virus-neutralizing antibody (Fig. 12) were not correlated with the 
protection level, because mice immunized with the mEIC + PIC + alum 
produced the same levels of neutralizing antibody as mice immunized with 
the mEIC + alum. 
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Fig. 11. Immunization with the hEIC co-delivered with PIC induced the 
production of Ebola virus-neutralizing antibodies in mice.  
Mice (n=5 per group) immunized as described for the challenge study 
Figs. 5 and 6), were bled 2 weeks after each immunization and 3 weeks 
after the last immunization. Pooled sera collected on day 84 were 
analyzed for neutralizing antibody specific to the Ebola virus. Serial 
dilutions of serum were mixed with Ebola virus and applied to Vero cell 
monolayers. Neutralization titers were determined to be the last dilution of 
serum that reduced the number of plaques by 80% compared with the 
control wells. 
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Fig. 12. Immunization with the mEIC + alum + PIC induced the production 
of Ebola virus-neutralizing antibodies in mice.  
Mice (n=5 per group) immunized as described for the challenge study (Fig. 
7 and 8) were bled 2 weeks after each immunization and 3 weeks after the 
last immunization. Pooled sera collected on day 84 were analyzed for 
Ebola virus-neutralizing antibodies. Serial dilutions of the sera were mixed 
with Ebola virus and applied to Vero cell monolayers. Neutralization titers 
were determined to be the last dilution of the serum that reduced the 
number of plaques by 80% as compared with control wells. 
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Immunization with EIC + PIC induced a mixed Th1/Th2 immune 
response that correlated with protection against virus challenge. 
The IgG isotope induced by immmunization can vary with the type 
of immunogen and the adjuvant used. In general, IgG2a is associated with 
a Th1-polarized response, and IgG1 is associated with a Th2 response. 
We compared the IgG isotypes (IgG1, IgG2a, IgG2b, and IgG3) induced 
by the hEIC with different adjuvants after each immunization; results are 
shown in Figs. 13, 14, 15, and 16. Immunization with the hEIC alone 
induced IgG1, IgG2b, and IgG3, but not IgG2a (Fig. 17A). When PIC or 
the combination of PIC + alum were co-administered with the hEIC, the 
IgG2a and an increase in the levels of IgG1, IgG2b, and IgG3 were 
induced (Fig. 17B and Fig. 17C, respectively), which showed a pattern 
similar to VRP-GP1 immunization (Fig. 17D). IgG1 was produced in the 
mice in all groups (Fig. 13), whereas IgG2a (Fig. 14) was produced only in 
mice immunized with VRP-GP1 or with the hEIC + PIC. Alum co-
administered with the hEIC induced low levels of IgG2a that were not 
significantly different from the levels of IgG2a induced by the hEIC 
administered alone or the PBS negative control groups (data not shown) 
(p=0.4533). In Fig. 15, IgG2b was produced in all groups, but the levels 
were higher in groups immunized with three doses of 25µg hEIC + PIC + 
alum, four doses of 10µg hEIC + PIC, and four doses of 10µg hEIC ≠ PIC 
+ alum, compared to groups receiving four doses of 10µg hEIC alone. The 
levels of IgG3 were very low in all groups (Fig. 16).  
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Fig. 13. The levels of IgG1 in the sera of mice immunized with the hEIC 
alone or with different adjuvants.  
Mice (n=5 per group) immunized with the hEIC as described for the 
challenge study (Figs. 5 and 6) were bled 2 weeks after each 
immunization and 3 weeks after the last immunization. Individual sera 
from days 0, 14, 35, 56, and 84 were analyzed for IgG1 specific to Ebola 
virus. The GMT for preimmune (day 0) serum in all groups were ≤ 1 (data 
not shown). The error bars indicate the SD. Statistically significant 
differences (p<0.05) in the level of the IgG anti-Ebola were determined by 
the Kruskal-Wallis test. Comparisons were made between immunization 
groups relative to the PBS control. * P < 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
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Fig. 14. The levels of IgG2a in the sera of mice immunized with the hEIC 
alone or with different adjuvants.  
Mice (n=5 per group) immunized with the hEIC as described for the 
challenge study (Figs. 5 and 6), were bled 2 weeks after each 
immunization and 3 weeks after the last immunization. Individual sera 
from days 0, 14, 35, 56, and 84 were analyzed for IgG2a specific to Ebola 
virus. The GMT for preimmune (day 0) serum in all groups were ≤ 1 (data 
not shown). The error bars indicate the SD. Statistically significant 
differences (p<0.05) in the level of the IgG anti-Ebola were determined by 
the Kruskal-Wallis test. Comparisons were made between immunization 
groups relative to the PBS control. * P < 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
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Fig. 15. The levels of IgG2b in the sera of mice immunized with the hEIC 
alone or with different adjuvants.  
Mice (n=5 per group) immunized with the hEIC as described for the 
challenge study (Figs. 5 and 6) were bled 2 weeks after each 
immunization and 3 weeks after the last immunization. Individual sera 
from days 0, 14, 35, 56, and 84 were analyzed for IgG2b specific to the 
Ebola virus. The GMT for preimmune (day 0) serum in all groups were ≤ 1 
(data not shown). The error bars indicate the SD. Statistically significant 
differences (p<0.05) in the level of IgG anti-Ebola were determined by the 
Kruskal-Wallis test. Comparisons were made between immunization 
groups relative to the PBS control. * P < 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
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Fig. 16. The levels of IgG3 in the sera of mice immunized with the hEIC 
alone or with different adjuvants.  
Mice (n=5 per group) immunized with the hEIC as described for the 
challenge study (Figs. 5 and 6) were bled 2 weeks after each 
immunization and 3 weeks after the last immunization. Individual sera 
from days 0, 14, 35, 56, and 84 were analyzed for the IgG3 specific to the 
Ebola virus. The GMT for preimmune (day 0) serum in all groups were ≤ 1 
(data not shown). The error bars indicate the SD. Statistically significant 
differences (p<0.05) in the level of the IgG anti-Ebola were determined by 
the Kruskal-Wallis test. Comparisons were made between immunization 
groups relative to the PBS control. * P < 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
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Fig. 17. IgG isotypes induced by immunization of mice with the hEIC + PIC 
or hEIC + PIC +alum induced a mixed Th1/Th2 immune response.  
Mice (n=5 per group) immunized as described for the challenge study 
(Figs. 5 and 6), were bled 2 weeks after each immunization (days 14, 35, 
and 56) and 3 weeks after the last immunization (day 84). The anti-Ebola 
antibody isotypes were measured by ELISA. IgG1 (blue), IgG2a (red), 
IgG2b (green), and IgG3 (orange) levels are presented for mice 
immunized with (A) the hEIC, (B) the hEIC + PIC, (C) the hEIC + PIC + 
alum, and (D) VRP-GP1. 
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The hEIC induced the production of anti-6D8 antibody in mice. 
 To evaluate whether mice immunized with the hEIC produced IgG 
specific for the 6D8 epitope, a competition binding assay was performed. 
When the humanized mAb 6D8 was mixed with serum from the mice 
immunized with the hEIC + PIC or with VRP-GP1, the binding of the 
resulting mouse serum to Ebola virus was decreased (Fig. 18). The result 
suggests that plant-produced humanized mAb 6D8 competed with a 
component of the mouse serum for the binding sites on the Ebola virus 
particles, and implies that antibody specific to the 6D8 epitope exists in the 
serum of mice immunized with the hEIC and PIC.  
 
 
 
  145 
 
Fig. 18. Competition ELISA to examine serum antibody specific to the 6D8 
epitope in mice immunized with the hEIC + PIC or with VRP-GP1. 
Sera were pooled from mice immunized with hEIC + PIC or with the VRP-
GP1, diluted 1:10, 1:100, or 1:1000, and mixed with plant-produced 
humanized mAb 6D8. The mixtures were used to probe irradiated Ebola 
virus that was bound to an ELISA plate. Goat anti-mouse IgG conjugated 
with HRP was used to detect the bound mouse IgG. 
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DISCUSSION 
Since the first Ebola virus outbreak approximately 30 years ago, no 
vaccine or drug against the Ebola infection in humans has been approved. 
There are different types of Ebola vaccines in development. Previous 
studies have demonstrated that both humoral and cell-mediated immune 
responses are critical to mediate the protection against a lethal Ebola virus 
challenge (32, 44, 49, 65, 68, 69). In this study, we determined that the 
EIC produced in N. benthamiana leaves induced humoral immune 
responses in mice. We anticipate that the cell-mediated immune response 
induced by EIC will be examined with future research. 
In this study, purified hEIC and mEIC were produced in either 
normal wild type or humanized N-glycan N. benthamiana (57), which 
synthesize complex N-glycans without xylose and core α-1,3-fucose. 
Because the constructs that we used to produce both immune complexes 
have a SEKDEL sequence at the C-terminus, the proteins were expected 
to be retained in the ER and thus obtain similar N-glycan compositions in 
both the wild type and the humanized N-glycan plants. Both enzymes that 
were suppressed in the humanized N-glycan plants, β-1,2-
xylosyltransferase (XylT) and α-1,3-fucosyltransferase, are localized in the 
Golgi apparatus, and thus had no effect on the N-glycans on the EIC 
produced in the wild-type plants, if they were indeed retained in the ER.  
Many studies showed that an IC, the combination between antigen 
and monoclonal antibody against that antigen, can induce both arms of 
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the adaptive immune responses (1, 9, 40, 41). Most of these studies used 
a mixture of antigen and the antibody specific to that antigen. The only 
fusion IC that induced an immune response was the tetanus toxin 
fragment C (TTFC) IC, with the fusion of TTFC at the C-terminus of an 
anti-TTFC antibody (9). These studies indicated that the IC preferentially 
binds to antigen-presenting cells via the Fc receptor and induces the 
adaptive immune response. For the plant-produced EIC, the structure of 
the Ebola GP1 is unknown. It is possible that the GP1 might block the Fc 
region on the mAb 6D8 to which it is fused. This could explain why the EIC 
cannot bind to the Fc receptor on the antigen-presenting cell and thus 
cannot induce the adaptive immune response. Another possibility is that 
the humanized mAb 6D8 used in the hEIC might affect the 
immunogenicity of the hEIC in mice. 
Published studies demonstrated that the administration of the IC 
formed with xenogeneic antibody were not able to induce humoral and 
cell-mediated immune responses, whereas using a syngeneic antibody in 
the IC did induce both immune responses (40, 41). The researchers 
showed that mice immunized with human serum albumin (HSA) bound tp 
rabbit anti-HSA produced lower antibody responses to HSA compared 
with mice immunized with HSA bound to mouse anti-HSA. However, our 
comparison between the immunogenicity of the hEIC and the mEIC in 
mice showed no statistical difference in either the antibody levels or the 
protection against lethal Ebola virus challenge. The P value from the Mann 
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Whitney test of the antibody levels between the groups of mice immunized 
with four doses of the hEIC or four doses of the mEIC was 1; and the p 
value from the log rank test of the protection levels between the groups of 
mice immunized with four doses of the hEIC + alum + PIC or four doses of 
the mEIC + alum + PIC was 0.6389. This result indicates that using a 
syngeneic antibody in the plant-produced EIC could not increase its 
immunogenicity in mice. However, different adjuvants co-delivered with 
the EIC induced strong immune responses, leading to effective protection 
from lethal Ebola virus challenge. 
Several TLR agonists are currently being evaluated as adjuvants 
for vaccine development. Among all TLR agonists, TLR7/8 agonists, such 
as Resiquimod, Gardiquimod, CL075, and CL097, have been shown to 
enhance vaccine efficacy by inducing both specific humoral and cell-
mediated immune responses (8, 17, 36, 48). Moreover, many studies 
have demonstrated that PIC, a synthetic analog of double-stranded RNA 
(dsRNA), is an effective adjuvant of vaccines (11, 27, 37, 47, 55). The 
combination of PIC with other adjuvants also showed synergistic effects 
(2, 10, 22, 42, 72). Most studies showed that the combination of different 
immunostimulators could induce the immune response more effectively 
and DC could cross-prime CD8 T cells in vivo, which is essential for 
enhanced vaccine immunogenicity (15). PIC induced efficient cross-
presentation from mature DC (14). TLR3 engagement induced cross-
priming in virus-infected cells (53). Thus, conjugating the appropriate TLR 
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ligand to the vaccine might promote cross-presentation and help to elicit 
improved immunity.  
In this study, we focused on testing the adjuvant effect of TLR7/8 
and TLR3 agonists because TLR7/8 and TLR3 recognize single-stranded 
and double-stranded RNA, respectively. The Ebola virus has a negative 
sense RNA genome, and it uses double-stranded RNA as the 
intermediate in RNA replication. Thus, both TLRs should be activated 
when the cells are infected by the Ebola virus. From our data, use of 
CL097 (a highly water soluble derivate of R848) did not enhance antibody 
immune responses specific to the Ebola virus, but co-administration with 
PIC did (Fig.2). A  previous study showed that a combination of MyD88-
dependent and MyD88-independent pathway agonists created synergy, 
but the combination of CL097 and PIC in our study, which are MyD88-
dependent and MyD88-independent pathways agonists, respectively, did 
not yield a synergistic effect. This was borne out by the observation that 
the antibody levels were the same for the use of PIC alone as for the 
combination of PIC + CL097 (Fig. 4). From this result, PIC shows potential 
for use as an adjuvant for the Ebola vaccine, because it enhanced the 
antibody response specific to Ebola virus when co-delivered with the EIC. 
Thus, we chose to add PIC to the hEIC for immunization of mice in the 
challenge study. 
Alum was also added to the EIC to immunize another group of mice 
in the experiment, because it is the classical adjuvant for vaccines and 
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until recently, the only FDA-approved adjuvant for human use (7, 51). If 
the addition of alum could enhance the immune response produced with 
the EIC, it could prove practical for clinical trials in humans. We also 
tested the combination of PIC + alum, which is the combination between 
the immunostimulator and the classical adjuvant, respectively. Our data, 
however, showed that the levels of antibody specific to Ebola virus in the 
group of mice immunized with the hEIC alone and the hEIC + alum were 
not statistically different (p=0.7715) (Fig. 6a). The mice in both groups 
were not protected from the lethal Ebola virus challenge, which was 
similar to the mice in the PBS negative control group (Fig. 5a). This result 
implies that alum failed to induce specific anti-Ebola immunity in a murine 
system. In contrast, PIC co-administered with the hEIC induced high 
levels of total IgG and neutralizing antibody specific to the Ebola virus 
(Fig. 6) and also provided protection from virus challenge (Fig. 5a). The 
antibody responses and the protection from Ebola virus challenge in the 
group immunized with the hEIC + PIC or in the group immunized with the 
hEIC + PIC + alum were not significantly different (p= 1 and 0.9480, 
respectively). This result confirms that hEIC + alum cannot induce a strong 
immune response and the combination of alum + PIC did not create any 
synergistic enhancement. However, co-administering PIC with the the 
hEIC did show enhancement of the anti-Ebola antibody responses and 
protection against the virus challenge. Our research demonstrated that 
PIC is a promising and effective adjuvant for an Ebola virus vaccine. 
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PIC was determined to be a good adjuvant for vaccine 
development in previous studies, because it can induce inflammation and 
long-lasting T cell immunity (52, 55, 60). PIC showed the induction of IL12 
(62) and type I interferon (59) via TLR3 and the adaptor protein, TRIF 
(12). Moreover, it was able to induce a Th1 response to human 
papillomavirus in rhesus macaques (55). PIC directly enhanced the 
survival of activated CD4 T cells both in vitro and in vivo (21). It was 
observed that fully functional CD8 memory cells were generated without 
CD4 help in the presence of PIC (23). PIC was used in a phase I-II trial in 
patients with leukemia, but the trial was stopped due to the toxicity of the 
treatment (50). In animals vaccinated with the peptide and PIC, the 
response was optimal only when PIC was immunized at the same time as 
the peptide, and the response was partially dependent on cytokines 
produced by NK cells (52).  
In our study, PIC showed the potential to adjuvant an adaptive Th1 
immunity, because there was an increase observed in IgG2a in mice 
immunized with the hEIC co-delivered with PIC, whereas there was no 
IgG2a found in the serum of mice immunized with the hEIC alone (Fig. 5). 
The presence of IgG2a indicates a Th1 response. VRP-GP1 also showed 
the induction of all IgG subtypes, which is similar to the hEIC co-
administered with PIC, and these groups were not statistically different in 
the protection against the lethal Ebola challenge. Immunization with the 
hEIC alone induced Th2, but not Th1, immune responses, because no 
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IgG2a was induced. Moreover, alum co-administered with the hEIC did not 
increase the level of IgG2a. This supports previous studies that alum 
predominantly induced the differentiation of the Th2 cells and mediated an 
antibody immune response (54). The hEIC alone and the hEIC + alum 
groups both showed the induction of Th2, but not Th1, immune responses, 
and all mice in these two groups died from the virus challenge. In contrast, 
the mice immunized with the hEIC + PIC, the hEIC + alum + PIC, and 
VRP-GP1 showed the induction of both Th1 and Th2 immune responses, 
and 80-90% of the mice in these groups survived the Ebola virus 
challenge. This implies that protection from the virus challenge requires a 
mixed Th1/Th2 immune response. In another study, the anti-GP mAb that 
was efficient in protecting mice from the virus challenge was 
predominantly IgG2a (69). This evidence supports the use of PIC with the 
EIC in ours study, because these mice produced more IgG2a than those 
that did not receive PIC. 
Although we did not test the protective efficacy against a lethal 
Ebola virus challenge in mice that were treated with PIC alone (without the 
antigen), the protection that we observed likely resulted from a 
combination of the EIC and PIC. PIC was shown to induce type I 
interferon (59), and the interferon system is one of the earliest host 
defenses, becoming operative within hours of infection, and is recognized 
as a potent antiviral agent. However, the expression of interferon is 
transient, decreasing 4 days after induction (4). Therefore, it is unlikely 
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that PIC treatment without the antigen could protect the mice challenged 3 
weeks after their last immunization, because the level of antiviral 
interferon would not be high enough 3 weeks after treatment. This 
suggests that the protection against a lethal Ebola challenge occurred 
from the effect of a combination of the EIC and PIC, and not from PIC 
alone.  
 As shown in Fig 11, the hEIC co-administered with PIC or a 
combination of PIC and CL097 induced the production of neutralizing 
antibody specific to Ebola virus. However, VRP-GP1, which protected the 
mice from a lethal challenge, did not induce the neutralizing antibody. This 
indicates that the neutralizing antibody is not the only factor that can 
protect against an Ebola infection. Although VRP-GP1 did not induce 
neutralizing antibody specific to the Ebola virus, it induced a cytotoxic T 
cell response, which mediates protection (44). The cytotoxic T cell induced 
by the EIC will be evaluated in the future. However, we believe that a 
prime-boost strategy that utilizes immunization with both VRP-GP1 and 
hEIC + PIC could enhance protective efficacy by providing both cellular 
and humoral immunity. 
We found that immunization with the hEIC + PIC combination or 
with VRP-GP1 induced the production of IgG specific for the 6D8 epitope 
in Ebola GP1, because the plant-produced humanized mAb 6D8 inhibited 
the binding to Ebola virus (Fig.18). This is an important finding because it 
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suggests that the formation of an immune complex did not prevent the 
presentation of the 6D8 epitope.   
In conclusion, this study presented the first evidence that protection 
against the lethal Ebola virus challenge can be afforded by plant-produced 
EIC in mice. This study also demonstrated that PIC is a good adjuvant for 
the EIC because it can induce antibody responses against Ebola virus, a 
mixed Th1/Th2 response, and protection from Ebola virus infection. In 
future research, the EIC will be tested for its ability to confer protection 
against an Ebola lethal challenge in non-human primates. 
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Chapter 5 
CONCLUSION 
Plants have been used as bioreactors to produce therapeutic 
proteins for more than 20 years. Besides the low cost and large-scale 
production of safe and biologically active mammalian proteins, plants also 
are able to perform most post-translational modifications required for 
biological activity and suitable pharmacokinetics of recombinant 
therapeutic proteins. Among the many plant species, such as cereals, 
legumes, vegetables, and fruit plants, investigated for their ability to 
produce biopharmaceuticals, outstanding features are possessed by two 
tobacco species—Nicotiana tabacum and Nicotiana benthamiana. Foreign 
proteins can be expressed in these plants through either transient 
expression or stable transformation. N. benthamiana was shown to be 
useful in producing various therapeutic proteins. In this study, we used N. 
benthamiana as a bioreactor to produce the EIC. 
 The antigen-antibody immune complexes are able to activate both 
humoral and cell-mediated immune responses. The administration of the 
antigen in the form of an IC enhances the capacity of DC to prime CD4+ 
and CD8+ cytotoxic T cells. Thus, the uptake of Ag in the IC is improved, 
compared with uptake of soluble Ag. Due to these capacities of the IC, it 
has potential to be applied to vaccine development. 
The goal of this dissertation was to develop an EIC from N. 
benthamiana for use as an Ebola vaccine. To produce the EIC, Ebola 
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glycoprotein (GP1) was fused at the C-terminus of the heavy chain of 
humanized IgG monoclonal antibody (mAb) 6D8, which specifically binds 
to a linear epitope on GP1. Co-expression of the GP1-heavy chain fusion 
and the 6D8 light chain using a geminiviral vector in N. benthamiana 
leaves produced an assembled immunoglobulin, which was purified by 
ammonium sulfate precipitation and protein A/G affinity chromatography. 
The IC formation was confirmed by a C1q binding assay, which showed 
that the recombinant protein bound to the complement factor C1q more 
effectively than antibody alone. Size measurements of the purified 
recombinant protein suggested that the EIC contained four to six 
molecules. Mice were subcutaneously immunized with the purified EIC 
and showed production of anti-Ebola antibodies. 
 Although the immunized mice produced antibodies against Ebola 
virus, the level of the antibody was not high enough to protect the mice 
from Ebola infection. The humanized antibody was replaced with mouse 
mAb 6D8 to produce the mEIC since previous studies had demonstrated 
that using syngeneic antibody in antigen-antibody immune complexes 
could induce both humoral and cell-mediated immune responses. 
However, the levels of anti-Ebola antibody produced with immunization 
with either the mEIC or the hEIC were observed to be similar. This 
indicates that using syngeneic antibody in our EIC did not increase the 
efficacy of the IC. To improve the immunogenicity of the EIC, different 
adjuvants were tested with the EIC . 
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In this study we evaluated the adjuvant effect of two TLR agonists 
co-delivered with the EIC. Mice were immunized subcutaneously in four 
doses with the EIC alone, or with the EIC co-administered with a TLR3 
agonist (PIC) or with a TLR7/8 agonist (CL097), alone or in combination 
with PIC. The use of PIC showed good results as an adjuvant for the 
plant-produced EIC, because the mice immunized with the EIC + PIC 
produced high antibody response against Ebola virus. In contrast, CL097 
was not a good adjuvant for the EIC, because it did not enhance the 
immune responses when immunized with the EIC. Furthermore, the 
combination of PIC and CL097 did not result in a synergistic 
enhancement. 
To determine the efficacy of the EIC as an Ebola vaccine, the 
immunized mice were intraperitoneally injected with 30,000 LD50 live 
Ebola virus. The immunization with the EIC + PIC protected 80% of the 
mice from a lethal Ebola virus challenge, comparable to the VRP-GP1 
positive control. Alum was also tested as an adjuvant by immunizing mice 
with the EIC + alum, but only 20% of the mice were protected. These data 
support PIC as an effective adjuvant for the EIC. 
The profile of IgG subtypes showed that the EIC alone induced a 
predominant Th2 immune response, as indicated by the production of 
IgG1, but no IgG2a. However, a mixed Th1/Th2 response was produced 
in mice immunized with EIC + PIC, and the mice in this group were 
protected from the Ebola infection. This suggests that a mixed Th1/Th2 
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immune response may be necessary for the protection against lethal 
Ebola virus challenge. 
 In the immunization study, we used VRP-GP1 as the positive 
control because it has been shown to protect mice from Ebola infection in 
previous studies. Since VRP-GP1 is an alphavirus vector, it undergoes 
limited replication in antigen-presenting cells of the immunized host, thus 
creating a viral replicon RNA that can act as a powerful adjuvant through 
Toll-like receptor signaling. Although VRP-GP1 could not stimulate the 
production of neutralizing antibody against the Ebola virus, it enhanced 
the antibody response specific to Ebola virus, induced a mixed Th1/Th2 
response, and conferred protection against the lethal Ebola virus 
challenge. Thus, the comparable response with the use of the plant-
derived EIC is a significant observation that indicates strong potential for 
the efficacy of a plant-produced EIC vaccine. 
 The production cost of our EIC is likely to be substantially lower 
than for VRP-GP1 production, which requires mammalian cell culture. The 
vaccine efficacy of the EIC might be improved by several different 
strategies: for instance, testing different linkers used between the mAb 
6D8 heavy chain and the GP1, using genetically engineered N. 
benthamiana to produce the EIC with human glycosylation, using a 
truncated GP1 to produce the EIC, increasing the dose of the EIC, trying a 
different prime-boost strategy, or testing the stability of the EIC after 
freeze-drying. 
  168 
 In conclusion, the EIC was produced in N. benthamiana leaves 
using a geminiviral replicon system. The protein was purified with 
ammonium sulfate precipitation and protein A/G affinity chromatography to 
remove most plant proteins. The EIC co-delivered with PIC induced high 
levels of total IgG antibody and neutralizing antibody specific to the Ebola 
virus, activated mixed Th1/Th2 responses, and protected mice from a 
lethal Ebola challenge. These results support the plant-produced EIC as a 
good vaccine candidate against Ebola virus infection. 
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Appendix A 
COMPARISON OF THE EIC EXPRESSION BETWEEN THE 
GEMINIVIRAL REPLICON AND THE ICON SYSTEM 
Objective 
To compare the expression level of the humanized Ebola immune 
complex (hEIC) expressed from different constructs of the Geminiviral 
replicon and the ICON systems. 
Materials and Methods 
The geminivector constructs were described in Chapter 2. For 
magnICON constructs, Hgp(TMV) and K(PVX) were infiltrated with 
pICH17388, pICH21380, and pICH14011 (1) at final OD600 0.2. Plants 
were maintained in a growth chamber, and the leaves were harvested on 
day 4 after infiltration. Soluble proteins were extracted by grinding the 
leaves with a fastprep machine in 1ml of extraction buffer (phosphate-
buffered saline (PBS), pH 7.5, leupeptin, and 0.1% Tween-20) per 0.1mg 
of leaves. After centrifugation at 13,000 rpm for 5 min, the supernatant 
was retained for subsequent analysis by ELISA (Materials and Methods in 
Chapter 2). 
Result and Discussion 
The IgG expression was analyzed by ELISA and shown in Fig. 1. 
The expression level of the geminivector using pBYRH2GP1kdel is the 
highest. Thus we continued to use this construct for all the hEIC 
production. As shown in Chapter 2, Fig. 6, purified hEIC presented 
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different protein species when detected with the anti-human heavy chain, 
due to protein degradation. The ELISA result represented the IgG 
expression. Because of the degradation, the level of the EIC is less than 
the IgG level. 
Reference 
1. Giritch, A., S. Marillonnet, C. Engler, G. van Eldik, J. 
Botterman, V. Klimyuk, and Y. Gleba. 2006. Rapid high-yield 
expression of full-size IgG antibodies in plants coinfected with 
noncompeting viral vectors. Proc Natl Acad Sci U S A 103:14701-6. 
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Fig. A1. IgG expression in N. benthamiana leaves 
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Appendix B 
COMPARISON OF THE EIC EXPRESSION AMONG DIFFERENT GP1 
TRUNCATIONS 
 Different truncations of the GP1 were designed and constructed as 
shown in Fig.1—H2GP312 and H2GP355. The expression levels of the 
EIC from each of these constructs were measured by ELISA (Fig. 2). 
There is no significant difference among the EIC from full length GP1 and 
the EIC from H2GP312 and H2GP315. Moreover, the C1q binding assay 
confirmed that all three different versions of EIC bind to C1q similarly. 
 
 
 
 
 
Fig. B1. Schematic representation of the full length and truncated Ebola 
GP1 fused to the C-terminus of the heavy chain of the mAb 6D8. 
H2GP312 has 158 amino acids (aa) of the GP1 from the C-terminus, 
whereas H2GP355 has 115 aa of GP1 from the C-terminus fused to the 
heavy chain.  
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Fig. B2. The expression levels of EIC containing full length GP1 or 
different truncations of GP1. 
  
Fig. B3. C1q binding of EIC containing full length GP1 compared to 
different truncations of GP1.  
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Appendix C 
A NOVEL SYSTEM for PRODUCING PHARMACEUTICAL PROTEINS IN 
HYBRID MAIZE 
The objective was to test the development of a bipartite Gemini 
virus gene expression system in corn cell cultures. Cell lines containing 
the LIR and SIR sites and a reporter gene (GUS) were produced and 
retransformed with either a construct containing the Rep or a control 
construct. Levels of protein expression can be used to confirm high levels 
of replication upon “activation” with the Rep. 
A gene expression construct pSCS20 using components of the 
Wheat Dwarf Virus (WDV) for GUS expression was designed and 
produced, and is shown in Fig. 1. The construct would then be used to 
genetically engineer the BMS cells. Transgenic BMS cells would be re-
transformed with a construct containing the Rep gene from WDV, using 
pSCS24 or pSCS25 (Fig.2 and Fig.3). pSCS24 contained the Rep under 
the BLT4.9 promoter which is a weak promoter, whereas pSCS25 
contained the Rep under the 35S promoter which is a strong promoter. 
The Rep gene would initiate excision on replication of the construct, 
including the scorable marker gene. The amount of expression could be 
tested and compared to non-induced transgenic lines. 
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Fig. C1. Map of pSCS20. 
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Fig. C2. Map of pSCS24. 
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Fig. C3. Map of pSCS25 
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The transformation was done via particle-mediated gene insertion 
using a BioRad PDS 1000 He. The coating of the gold particle with DNA 
was performed using BioRad recommended protocol. Gold was 1.0 
micron at 60mg/ml concentration. Gun parameters were chosen from 
those recommended by BioRad and as described in the protocol from the 
University of Minnesota. The rupture pressure was 1100 PSI, vacuum of 
27.5 in of Hg, 1/4-in gap distance and 9cm from the stopping screen to the 
target tissue. 
 After we obtained the stable BMS cell line containing pSCS20 and 
re-transformed either pSCS24 or pSCS25, PCR to detect Rubisco as an 
internal control, GUS gene, and circular form were performed, and results 
are shown in Fig. 4. From the PCR screen, the GUS gene was detected in 
some clones, but the circular form, which is the intermediate Geminivector 
replication, was not detected. To summarize, the WDV Rep, transiently 
expressed in stable BMS cell lines containing the GUS gene in the WDV 
replicon, could not cut and amplify GUS in the WDV replicon. Thus, the 
expression of GUS did not increase.  
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Fig. C4. PCR screen for Rubisco, GUS, and the circular form.  
 
